Bi-specific antibodies and uses thereof

ABSTRACT

Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

This application contains a Sequence Listing in computer readable form.

The computer readable form is incorporated herein by reference. Thisapplication is a Continuation application of the pending U.S. patentapplication Ser. No. 15/123,243 filed on Sep. 1, 2016, which is theNational Stage of International Application No. PCT/US2015/018365 filedon Mar. 2, 2015, which claims priority to U.S. Provisional ApplicationNo. 61/946,997, filed Mar. 3, 2014, and U.S. Provisional Appl. No.61/946,980, filed Mar. 3, 2014. The entire contents of these documentsare incorporated herein by reference in their entireties.

BACKGROUND OF THE INVENTION 1. Field of the Invention

The present disclosure relates to treatments of cancers. Specifically,the present disclosure relates to novel bi-specific antibodies and theiruses for suppressing the growth or metastasis of cancers; and trackingthe development of cancers.

2. Description of Related Art

Covalent attachment of poly(ethylene glycol) (PEGylation) to substancessuch as proteins, peptides, and nanoparticles (NPs) (e.g., liposomes,micelles, and the like) can increase drug bioavailability, enhance bloodcirculation half-life and hinder capture by the reticuloendothelialsystem (RES). These favorable attributes have led to the widespread useof PEGylation in the development of NPs including those available inclinical use, such as liposomal doxorubicin (Caelyx) for the treatmentof ovarian and breast carcinomas and Kaposi's sarcoma and Genexol-PM®(Paclitaxel-loaded PEG-PLA micelles), approved for metastatic breastcancer, non-small cell lung cancer and ovarian cancer in South Korea.PEGylated nanoparticles (PEG-NPs) are highly regarded as the secondgeneration of drug delivery systems and the mainstream of therapeutic orimaging agents.

PEGylated substances, particularly, PEG-NPs can accumulate in tumors dueto the enhanced permeability and retention (EPR) effect caused by theabnormal structure of endothelial cells in tumors. PEG-NPs, however,often accumulate near tumors but do not penetrate into the tumor mass,and some drugs cannot easily diffuse from PEG-NPs to cancer cells.Therefore, several studies reported that chemical conjugation ofantibodies to PEG-NPs increases specific targeting and intracellularuptake which improves therapeutic efficacy and the sensitivity ofimaging. However, chemically linking antibodies to PEG-NPs is difficultto achieve. Most functional groups (e.g., amino, carboxyl, thiol groups)are abundant in ligands, which may cause loss of antibody function, orresult in heterogeneous orientation of the antibody, thereby renderingit difficult to obtain a reproducible product after chemicalconjugation. Further, chemical conjugation may also alter the structureof nano-carriers and encapsulated drugs. These problems limit theclinical applicability of targeted NPs.

In view of the foregoing, there exist in the related art, a need for animproved way of targeting PEGylated substances (e.g., PEG-NPs), which isreproducible and easy to use.

SUMMARY

The present disclosure provides humanized bi-specific antibodies andtheir uses for treating cancers or for tracking development of cancers.

Accordingly, it is the first object of the present disclosure to providea bi-specific antibody (BsAb) that bind to two different epitopes, whichare a PEG molecule (e.g., the terminal methoxy or hydroxyl group of thePEG, or the backbone of the PEG) and a target ligand (e.g., an epidermalgrowth factor receptor (EGFR), TAG72, CD19, or CD20). The BsAb of thepresent disclosure includes a first antigen binding site that binds toPEG and comprises a first light chain variable domain and a first heavychain variable domain; a second antigen binding site that binds to atarget ligand (e.g., a tumor antigen). Preferably, the BsAb of thepresent disclosure further includes a peptide linker between the firstantigen binding site and the second antigen binding site. Optionally,the first antigen binding site may further include a first hinge domain.

The target ligand may be a protein selected from the group consisting ofepidermal growth factor receptor (EGFR), human epidermal growth factorreceptor (HER2), HER3, tumor-associated glycoprotein 72 (TAG-72), CD19and, CD20.

In some embodiments, the first antigen binding site of the BsAb binds tothe backbone of PEG and comprises a first VL-Cκ domain at least 90%identical to SEQ ID NO: 1, a first VH-CH1 domain at least 90% identicalto SEQ ID NO: 2, and a first hinge domain at least 90% identical to SEQID NO: 3; while the second antigen binding site of the BsAb binds to anyof TAG-72, EGFR, or HER2 and comprises a single chain variable fragment(scFv) at least 90% identical to SEQ ID NO: 5, 7, or 8; and the peptidelinker is at least 90% identical to SEQ ID NO: 4.

In some embodiments, the first antigen binding site binds to thebackbone of PEG with the first VL-Cκ domain at least 90% identical toSEQ ID NO: 9, and the first VH-CH1 domain at least 90% identical to SEQID NO: 10; while the second antigen binding site binds to EGFR or CD19and comprises a scFv at least 90% identical to SEQ ID NO: 7 or 11; andthe peptide linker is at least 90% identical to SEQ ID NO: 4.

In other embodiment, the first antigen binding site binds to thebackbone of PEG and comprises a first VL-Cκ domain at least 90%identical to SEQ ID NO: 9, a first VH-CH1 domain at least 90% identicalto SEQ ID NO: 10, and a first HR-CH2-CH3 domain at least 90% identicalto SEQ ID NO: 22; while the second antigen binding site binds to CD19 orHER2 and comprises a second VL-CH1 domain at least 90% identical to SEQID NO: 23 or 26, a second VH-Cκ domain at least 90% identical to SEQ IDNO: 24 or 27, and a second HR-CH2-CH3 domain at least 90% identical toSEQ ID NO:25.

In another embodiment, the first antigen binding site binds to theterminal methoxy or hydroxyl group of PEG and comprises a first VL-Cκdomain at least 90% identical to SEQ ID NO: 12, a first VH-CH1 domain atleast 90% identical to SEQ ID NO: 13, and a first HR-CH2-CH3 domain atleast 90% identical to SEQ ID NO: 22; while the second antigen bindingsite binds to CD19 or HER2 and comprises a second VL-CH1 domain at least90% identical to SEQ ID NO: 23 or 26, a second VH-Cκ domain at least 90%identical to SEQ ID NO: 24 or 27, and a second HR-CH2-CH3 domain atleast 90% identical to SEQ ID NO: 25.

In still another embodiment, the first antigen binding site binds to theterminal methoxy or hydroxyl group of polyethylene glycol (PEG) andcomprises a first VL-Cκ domain at least 90% identical to SEQ ID NO: 12,a first VH-CH1 domain at least 90% identical to SEQ ID NO: 13, and afirst HR-CH2-CH3 domain at least 90% identical to SEQ ID NO: 22; whilethe second antigen binding site binds to HER2 or EGFR, and comprises ahumanized single chain variable fragment (scFv) at least 90% identicalto SEQ ID NO: 15 or 16.

In further embodiments, the first antigen binding site binds to theterminal methoxy or hydroxyl group of polyethylene glycol (PEG) andcomprises a humanized single chain variable fragment (scFv) at least 90%identical to SEQ ID NO: 17; while the second antigen binding site bindsto CD19 or CD20 and comprises a first VL-Cκ domain at least 90%identical to SEQ ID NO: 21, a first VH-CH1 domain at least 90% identicalto SEQ ID NO: 20.

It is the second object of the present disclosure to provide apharmaceutical kit for treating or tracking the development of cancers,including metastatic and/or drug-resistant cancers. The pharmaceuticalkit includes at least, two components, which are respectively thebi-specific antibody described above; and a PEGylated substance that iseither a therapeutic agent or an imaging agent. The therapeutic agentmay be any of a protein, a peptide, or a nanoparticle containing thereina chemotherapeutic drug. The imaging agent may be a quantum dot (QD), amicrobubble contrast agent, a fluorescence dye, an iron nanoparticle, achelated radioisotope or a gold nanoparticle.

In practice, the bi-specific antibody and the PEGylated substance of thepharmaceutical kit are first mixed to form an assembly; and the assemblyis then administered to the subject for treating cancers or for trackingcancers.

It is thus the third object of the present disclosure to provide amethod of treating a subject suffering from the growth of a cancer. Themethod includes the steps of, administering the bi-specific antibodydescribed above and a PEGylated substance containing a therapeuticagent, concurrently or sequentially to the subject in a dose sufficientto inhibit the growth or metastasis of the cancer of the subject.Preferably, the method comprises the steps of mixing the bi-specificantibody described above and the PEGylated substance containing atherapeutic agent to form an assembly, and administering the assembly tothe subject in a dose sufficient to inhibit the growth or metastasis ofthe cancer of the subject. The dose administered to the subject is fromabout 0.1 to 50 mg/Kg body weight of the subject. In certainembodiments, the dose is administered to the subject from about 1 to 40mg/Kg body weight of the subject, preferably from about 5 to 10 mg/Kgbody weight of the subject. The dose can be administered in a singledose, or alternatively in more than one smaller doses.

Cancers, preferably those exhibit increased expression levels of EGFR,HER2, TAG72, CD19 or CD20 are treatable by the method of the presentdisclosure. In preferred embodiments, the method of the presentdisclosure is effective for treating a subject having breast cancer,head and neck cancer, colorectal cancer or ovarian cancer.

It is the fourth object of the present disclosure to provide a method ofimaging tissues in a live subject. The method includes steps of,administering the bi-specific antibody described above and a PEGylatedsubstance containing a therapeutic agent, concurrently or sequentiallyto the subject in an amount sufficient to imagine the tissues in thesubject. Preferably, the method includes steps of: (a) mixing a firstsufficient amount of any of the humanized bi-specific antibody of thepresent disclosure and a second sufficient amount of a PEGylatedsubstance (e.g., a nanoparticle containing therein an imagine agent suchas a quantum dot (PEG-QD) or a fluorescent dye) to form an assembly; (b)injecting the assembly of the step (a) to the subject; and (c) imagingthe tissues of the subject by fluorescence imaging, electron spinresonance (ESR) imaging, gamma camera imaging, X-ray imaging, computedtomography (CT), or magnetic resonance imaging (MRI). According to someembodiments, the PEG-QD comprises a quantum dot nanocrystal selectedfrom the group consisting of CdHgTe, CdSe, CdSe/ZnS, CdS, CdTe,CdTe/CdS, PbSe and PbS.

The details of one or more embodiments of the invention are set forth inthe accompanying description below. Other features and advantages of theinvention will be apparent from the detail descriptions, and fromclaims.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed incolor. Copies of this patent or patent application publication withcolor drawing(s) will be provided by the Office upon request and paymentof the necessary fee.

These and other features, aspects and advantages of the presentinvention will become better understood with reference to the followingdescription, appended claims and the accompanying drawings, where:

FIG. 1 is a schematic diagram of IgG antibody with the domainsindicated;

FIG. 2A is a schematic diagram of a dimeric BsAb structure in accordanceto one embodiment of the present disclosure;

FIG. 2B is a schematic diagram of a monomeric BsAb structure inaccordance to one embodiment of the present disclosure;

FIG. 2C is a schematic diagram of a monomeric BsAb structure inaccordance to another embodiment of the present disclosure;

FIG. 2D is a schematic diagram of a “knob in hole” BsAb structure inaccordance to one embodiment of the present disclosure;

FIG. 2E is a schematic diagram depicting the modified “knob in hole”BsAb structure having crossover heavy and light chains in accordance toone embodiment of the present disclosure;

FIG. 3 is a schematic diagram illustrating the one-step targeting andtreating cancer by use of the humanized anti-mPEG BsAbs in accordance toone embodiment of the present disclosure;

FIG. 4 depicts the binding of anti-mPEG antibody secreted by hybridoma15-2b to immobilized PEG molecules in accordance with one example of thepresent disclosure;

FIG. 5A is a schematic illustration of DNA constructs for humanizedanti-PEG (hE11) BsAbs of example 1.2 in accordance with one embodimentof the present disclosure;

FIG. 5B is a schematic drawing of the structure of the humanizedanti-PEG (hE11) BsAbs of example 1.2;

FIG. 5C illustrates the SDS-PAGE analysis of the humanized anti-PEG(hE11) BsAbs of example 1.2 in reducing or non-reducing conditions inaccordance with one embodiment of the present disclosure;

FIG. 5D illustrates the western blot analysis of the humanized anti-PEG(hE11) BsAbs of example 1.2 in accordance with one embodiment of thepresent disclosure;

FIGS. 6A to 6C respectively illustrate the antigen-binding activity ofthe humanized anti-PEG (hE11) BsAbs of example 1.2 towards (A) mucin,(B) BSA-PEG_(5,000) or (C) BSA in accordance with one embodiment of thepresent disclosure;

FIG. 7 illustrates the cancer cell selectivity of the humanized anti-PEG(hE11) BsAbs of example 1.2 in accordance with one embodiment of thepresent disclosure;

FIG. 8A illustrates the cancer cell selectivity of the dimeric humanizedanti-PEG (hE11) BsAbs of example 1.4 in Jurkat (TAG-72+), MDA-MB-468(EGFR+) or BT-474 (HER2+) cells in accordance with one embodiment of thepresent disclosure;

FIG. 8B illustrates the binding activities of the dimeric humanizedanti-PEG (hE11) BsAbs of example 1.4 with the PEGylated liposomal TexasRed in Jurkat (TAG-72+), MDA-MB-468 (EGFR+) or BT-474 (HER2+) cells inaccordance with one embodiment of the present disclosure;

FIG. 8C illustrates the binding activities of the dimeric humanizedanti-PEG (hE11) BsAbs of example 1.4 with the PEGylated Quantum Dot(Qdot655) in Jurkat (TAG-72+), MDA-MB-468 (EGFR+) or BT-474 (HER2+)cells in accordance with one embodiment of the present disclosure;

FIG. 9 is a schematic illustration of DNA constructs for humanizedmonovalent anti-PEG (hE11) BsAbs of example 2.1 and the structure of themonovalent BsAb in accordance with one embodiment of the presentdisclosure;

FIG. 10 illustrates the cancer cell selectivity of the humanizedmonovalent anti-PEG (hE11) BsAbs of example 2.1 in Jurkat (TAG-72+),MDA-MB-468 (EGFR+) or BT-474 (HER2+) cells in accordance with oneembodiment of the present disclosure;

FIG. 11 illustrates the binding activities of the humanized monovalentanti-PEG (hE11) BsAbs of example 2.1 with the PEGylated liposomal TexasRed in Jurkat (TAG-72+), MDA-MB-468 (EGFR+) or BT-474 (HER2+) cells inaccordance with one embodiment of the present disclosure;

FIG. 12 illustrates the binding activities of the humanized monovalentanti-PEG (hE11) BsAbs of example 2.1 with the PEGylated Quantum Dot(Qdot655) in Jurkat (TAG-72+), MDA-MB-468 (EGFR+) or BT-474 (HER2+)cells in accordance with one embodiment of the present disclosure;

FIG. 13A is a schematic illustration of DNA constructs for humanizedmonovalent anti-PEG (h6.3) BsAbs of example 2.2 and the structure of theBsAb in accordance with one embodiment of the present disclosure;

FIG. 13B illustrates the SDS-PAGE analysis of the humanized monovalentanti-PEG (h6.3) BsAbs of example 2.2 in reducing or non-reducingconditions in accordance with one embodiment of the present disclosure;

FIGS. 14A and 14B respectively illustrate the antigen-binding activityof the humanized monovalent anti-PEG (h6.3) BsAbs of example 2.2 towards(A) NH₂-PEG_(10,000)-NH₂ and (B) BSA in accordance with one embodimentof the present disclosure;

FIG. 14C illustrates the binding activities of the humanized monovalentanti-PEG (h6.3) BsAbs of example 2.2 with the PEGylated Quantum Dot(Qdot655) or PEGylated liposomal Texas Red in Raji (CD19+) or A431(EGFR+) cells in accordance with one embodiment of the presentdisclosure;

FIGS. 14D and 14E respectively illustrate the binding kinetics of thehumanized monovalent anti-PEG (h6.3) and antiCD19 BsAbs of example 2.2towards CH₃-PEG_(5,000)-Alexa647 in accordance with one embodiment ofthe present disclosure;

FIG. 15 is a panel of real-time images illustrating the endocyticactivity of the humanized monovalent anti-PEG (h6.3) BsAbs of example2.2 with the PEGylated Quantum Dot (Qdot655) in A431 (EGFR+) cells inaccordance with one embodiment of the present disclosure;

FIGS. 16A to 16C are line graphs respectively illustrate the enhancedin-vitro cytotoxity of Lipo/DOX by the humanized monovalent anti-PEG(h6.3) BsAbs of example 2.2 in (A) A431 cells (EGFR⁺), (B) MDA-MB-468cells (EGFR⁺) and (C) Raji cells (CD19+) in accordance with oneembodiment of the present disclosure;

FIG. 17 illustrates the tumor imaging enhancement of the humanizedmonovalent anti-PEG (h6.3) BsAbs of example 2.2 targeted PEG-NIR797against CD19 and EGFR tumor in accordance with one embodiment of thepresent disclosure;

FIG. 18A is a schematic illustration of DNA constructs for humanizedanti-mPEG BsAbs in accordance with one embodiment of the presentdisclosure;

FIG. 18B illustrates the SDS-PAGE analysis of the humanized BsAbs ofexample 2.3 in reducing or non-reducing condition in accordance with oneembodiment of the present disclosure;

FIGS. 18C and 18D illustrate the respective binding activities of thehumanized BsAbs of example 2.3 with the indicated PEG-NPs in SW480 cells(EGFR⁺) (FIG. 2C) and SK-BR-3 cells (HER2⁺) (FIG. 2D) in accordance withone embodiment of the present disclosure;

FIG. 19A illustrates the cancer cell selectivity of PEG-NPs treated withthe humanized BsAbs of example 2.3 in SW480 cells (EGFR⁺) and SW620cells (EGFR⁻) (FIG. 2C) in accordance with one embodiment of the presentdisclosure;

FIG. 19B illustrates the cancer cell selectivity of PEG-NPs treated withthe PEG×EGFR or PEG×HER2 of example 2.3 in SK-BR-3 cells (HER2⁺) andMDA-MB-468 cells (HER2⁻) in accordance with one embodiment of thepresent disclosure;

FIGS. 20A to 20D respectively illustrate the enhanced in-vitrocytotoxity of Lipo/DOX by PEG×EGFR of example 2.3 in (A) SW480 cells(EGFR⁺), (B) SW620 cells (EGFR⁻), (C) SK-BR-3 cells (HER2⁺), and (D)MDA-MB-468 cells (HER2⁻) in accordance with one embodiment of thepresent disclosure;

FIG. 21 is a panel of in vivo imaging of PEG×EGFR of example 2.3targeting Lipo/IR780 in accordance with one embodiment of the presentdisclosure; and

FIGS. 22A and 22B illustrate the respectively size of EGFR⁺ and EGFR⁻tumors treated with PEG×EGFR targeted Lipo/Dox in accordance with oneembodiment of the present disclosure; and

FIG. 22C is a line graph illustrating the changes in body weight of thetest animals in FIGS. 22A and 22B;

FIG. 23A is a schematic drawing of DNA constructs for humanizedanti-mPEG (h15-2b) anti-CD19 BsAb and anti-mPEG (h15-2b) anti-CD20 BsAbin accordance with one embodiment of the present disclosure;

FIG. 23B illustrates the cancer cell selectivity of the BsAbs of example2.4 in Raji cells in accordance with one embodiment of the presentdisclosure;

FIG. 23C illustrates the mPEG binding activity of the BsAbs of example2.4 in accordance with one embodiment of the present disclosure;

FIG. 23D illustrates the dual binding activity of the BsAbs of example2.4 in accordance with one embodiment of the present disclosure;

FIG. 24A is a schematic illustration of DNA constructs for humanizedknob in hole anti-PEG (h15-2b) BsAbs of example 3.1 and the structuresof the BsAbs in accordance with one embodiment of the presentdisclosure;

FIG. 24B is a schematic illustration of DNA constructs for humanizedknob in hole anti-PEG (h6.3) BsAbs of example 3.1 and the structures ofthe BsAbs in accordance with one embodiment of the present disclosure;

FIG. 24C illustrates the SDS-PAGE analysis of the humanized knob in holeanti-PEG (h15-2b or h6.3) BsAbs of example 3.1 in non-reducing conditionin accordance with one embodiment of the present disclosure;

FIG. 25 illustrates the cancer cell selectivity of the humanized knob inhole anti-PEG (h15-2b) BsAbs of example 3.1 in Ramous (CD19⁺), Raji(CD19⁺) and SKBR3 (HER2⁺) cells in accordance with one embodiment of thepresent disclosure;

FIG. 26 illustrates the dual binding activities of the humanized knob inhole anti-PEG (15-2b) BsAbs of example 3.1 with the PEGylated QuantumDot (Qdot655) in Ramos (CD19⁺), Raji (CD19⁺) and SKBR3 (HER2⁺) cells inaccordance with one embodiment of the present disclosure;

FIG. 27 illustrates the cancer cell selectivity of the humanized knob inhole anti-PEG (h6.3) BsAbs of example 3.1 in Ramos (CD19⁺), Raji (CD19⁺)and SKBR3 (HER2⁺) cells in accordance with one embodiment of the presentdisclosure;

FIG. 28 illustrates the dual binding activities of the humanized knob inhole anti-PEG (h15-2b or h6.3) BsAbs of example 3.1 with the PEGylatedQuantum Dot (Qdot655) in Raji (CD19⁺) and SKBR3 (HER2⁺) cells inaccordance with one embodiment of the present disclosure;

FIG. 29 is a schematic illustration of DNA constructs for BsAbs ofexample 4.1 in accordance with one embodiment of the present disclosure;

FIGS. 30A and 30B respectively illustrate the enhanced in-vitrocytotoxicity of Lipo/DOX by BsAbs of example 4.1 in (A) SKBR3 cells(HER2⁺) and (B) A431 cells (EGFR⁺) in accordance with one embodiment ofthe present disclosure; and

FIGS. 31 A and 31B respectively illustrate the synergistic anti-cancereffects of Lipo/DOX by BsAbs of example 4.1 in (A) SKBR3 cells (HER2⁺)and (B) A431 cells (EGFR⁺) in accordance with one embodiment of thepresent disclosure; and

FIG. 32 illustrates the synergistic anti-cancer effects of Lipo/DOX byBsAbs of example 4.1 in SKBR3 cells (HER2⁺) in accordance with oneembodiment of the present disclosure.

DESCRIPTION

The detailed description provided below in connection with the appendeddrawings is intended as a description of the present examples and is notintended to represent the only forms in which the present example may beconstructed or utilized. The description sets forth the functions of theexample and the sequence of steps for constructing and operating theexample. However, the same or equivalent functions and sequences may beaccomplished by different examples.

I. Definition

The term “antibody” is used in the broadest sense and specificallycovers monoclonal antibodies, polyclonal antibodies, multispecificantibodies (e.g., bi-specific antibodies), and antibody fragments solong as they exhibit the desired biological activity, that is, tospecifically bind to an antigen when it preferentially recognizes itstarget antigen in a complex mixture of proteins and/or other molecules.

The term “monoclonal antibody” as used herein refers to an antibodyobtained from a population of substantially homogeneous antibodies, andis not to be constructed as requiring production of the antibody by anyparticular method. In contrast to polyclonal antibodies which typicallyinclude different antibodies directed to different epitopes, eachmonoclonal antibody is directed against a single determinant (i.e.,epitope) on the antigen. The monoclonal antibodies of the presentdisclosure may be made by the hybridoma method or by recombinant DNAmethods. The monoclonal antibodies herein specifically include“chimeric” or “recombinant” antibodies, in which a portion of the heavyand/or light chain is identical with or homologous to correspondingsequences in antibodies derived from a particular species or belongingto an antibody class or subclass, while the remainder of the chainidentical with or homologous to corresponding sequences in antibodiesderived from another species or belonging to another antibody class orsubclass, as well as fragments of such antibodies, as long as theyexhibit the desired biological activity.

“Humanized” forms of non-human (e.g., murine) antibodies are chimericantibodies which contain minimal sequence derived from non-humanimmunoglobulin. Humanized antibodies are human immunoglobulins in whichhypervarible region residues are replaced by hypervarible regionresidues from a non-human species such as mouse, rat, rabbit, ornon-human primate having the desired specificity or affinity. In someinstances, Fv framework region (FR) residues of the human immunoglobulinare replaced by corresponding non-human residues. In general, thehumanized antibody will comprise substantially all of at least one, andtypically two, variable domains, in which all or substantially all ofthe FR regions are those of a human immunoglobulin sequence. Thehumanized antibody may optionally comprise at least a portion of animmunoglobulin constant region (Fc), typically that of a humanimmunoglobulin.

An “isolated” antibody is one which has been identified and separatedand/or recovered from a component of its nature environment. Containmentcomponents of its nature environment are materials which would interferewith therapeutic uses of the antibody of this invention, and may includeenzymes, hormones, and other protenaceous or non-proteinaceous solutes.Isolated antibody includes the antibody in situ within recombinantcells. Ordinarily, isolated antibody will be prepared by at least onepurification step.

The term “bi-specific antibody (BsAb)” refers to an antibody havingspecificities for at least two different antigens. For example, BsAb mayhave one arm having a specificity for one antigenic site, such as atumor associated antigen, while the other arm recognizes a differenttarget, for example, a haptan that is bound to a lethal agent (e.g.,INF-α or a liposome containing an anti-cancer agent such as vincaalkaloid) or an imaging agent (e.g., a microbubble containing a contrastagent or a quantum dot or fluorescent dye). In preferred embodiments,the BsAb of the present disclosure has two antigen-binding sites, inwhich one is directed against a tumor antigen (e.g., TAG72, CD19, EGFRor HER2), while the other is directed against a hydrophilic polymer(e.g., polyethylene oxide (PEG)), that is bound to a nanoparticlecontaining a cancer therapeutic agent therein (e.g., Lipo/DOX).

The term “valent” as used herein refers to the presence of a specifiednumber of binding sites in an antibody molecule. As such, the term“monovalent”, “divalent”, “trivalent” and tetravalent” refer to thepresence of 1, 2, 3, and 4 binding sites, respectively in an antibodymolecule. The BsAb of the present disclosure is at least “divalent”, andmay be multivalent, such as tetravalent.

The term “linker” and “peptide linker” are interchangeably used in thepresent disclosure and refers to a peptide having natural or syntheticamino acid residues for connecting two polypeptides. For example, thepeptide linker may be used to connect the VH and the VL to form thesingle chain variable fragment (e.g., scFv); or to connect the scFv tothe full length antibody to form a BsAb of the present disclosure.Preferably, the linker is a peptide having at least 5 amino acidresidues in length, such as 5 to 100 amino acid residues in length, morepreferably 10 to 30 amino acid residues in length. The linker withinscFv is a peptide of at least 5 amino acid residues in length,preferably 15 to 20 amino acid residues in length. In one example, thelinker comprises a sequence of (G_(n)S)_(m), with G=glycine, S=serine, nis a number between 1 to 4, and m is 1, 2 or 3. Preferably, the linkercomprises a sequence of (G₄S)₃; or a sequence of (G₃S) and (G₃S₂).

The term “PEGylated substance” as used herein refers to a substancecoated with polyethylene glycol (PEG), which includes but is not limitedto, a protein (e.g., a chemokine), a peptide (e.g., leuprolide) and ananoparticle (NP) containing therein a therapeutic agent or an imagineagent. Materials known in the state of the art that may give rise to thenanoparticle includes mesoporpous silica, as well as the material thathas a hydrophilic portion and a hydrophobic portion that forms a micellestructure capable of including a therapeutic agent (e.g., anti-canceragent) or an imaging agent (e.g., a fluorescence dye, a quantum dot, achelated radioisotope, a paramagnetic iron, gold nanoparticle or acontrast agent) within its structure. Suitable materials for formingnanoparticles in the present disclosure include, but are not limited to,mesoporpous silica; phospholipids such as phosphatidylcholine (PC),phosphatidylethanolamine (PE), phosphatidylserine (PS),phosphatidylglycerol (PG), phosphatidic acid (PA), phosphatidylinositol(PI), sphingomyelin (SPM), and the like, alone or in combination;biodegrable polymer such as polylactic acid (PLA), polyglycolic acid(PGA) poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL),polydioxanone (PDO), polyanhydrides, polyorthoesters, chitosan and thelike, alone or in combination. Preferably, the PEGylated substance, suchas a PEGylated NP, further contains a cancer therapeutic agent or animagine agent within the micelle structure.

The terms “cancer” and “tumor” are used alternatively in the presentdisclosure and preferably refer to the physiological condition inmammals and especially in humans that is typically characterized byun-regulated cell growth. Cancers in this respect include metastasescancers, and/or drug-resistant cancers. Cancers, preferably thoseexhibit increased expression levels of TAG72, EGFR, HER2, CD19, andCD20. Accordingly, cancers or tumors treatable by the present disclosureare breast, lung, colon, colorectal, spleen, kidney, liver, bladder,head and neck, ovary, prostate, brain, pancreas, skin, bone, blood,thymus, uterus, testicles, cervix, and neuron. More specifically, thecancer is selected from the group consisting of breast cancer,colorectal cancer, head and neck cancer, colon cancer, hepatic cancer,non-Hodgkin's lymphoma, lymphoma, pancreatic cancer, lung cancer,gastric cancer, prostate cancer, brain tumor, retinoblastoma, ovariancancer, cervical cancer, hematopoietic malignances, esophageal cancer,renal cell carcinoma, squamous cell carcinoma, glioma, and leukemia

The term “therapeutic agent(s)” as used herein refers to an agentutilized to treat, combat, ameliorate, prevent or improve a disease or acondition, such as a cancer, in a patient. Accordingly, therapeuticagent(s) for treating cancer preferably refers to cytotoxic agents thatare known to improve the therapeutic effects of a cancer treatment;accordingly, cytotoxic agents as used in the present disclosure include,but are not limited to, radiation, chemotherapeutic agents, antibodies,and the like.

The term “drug-resistant cancer” as used herein refers to a cancer whosegrowth is not suppressed or retarded by the application of a well-knowncytotoxic agent, which may be a chemotherapeutic agent, an antibody, apeptide or a combination thereof. In some embodiments, the drug is achemotherapeutic agent. Examples of chemotherapeutic agent includealkylating agent such as nitrosoureas, cisplatin, or dacarbazine;antimetabolites such as folic acid, purine or pyrimidine antagonists;mitotic inhibitors such as vinca alkaloids; cytotoxic antibiotics andcamptothecin derivatives. Preferred chemotherapeutic agent includesadriamycin, amifostine, bleomycin, busulfan, cisplatin, and/or otherplatinum compounds, preferably including carboplatin and/or oxaliplatin,camptothecin, CPT-11, cytosine arabinoside, chlorambucil,cyclophosphamide, cytarabine, daunorubicin, doxorubicin, docetaxel,dacarbazine, dactinomycin, etoposide, 5-fluorouracil (5-FU),fluoxuridine, gemcitabine, hydroxyurea, ifosfamide, idarubicin,interferon beta, irinotecan, L-asparaginase, L-aspartic acid, lomustine,mechlorethamine, mitomycin, methotrexate, mitoxantrone, megestrol,melphalan, mercaptopurine, mitotane, paclitaxel (taxol), plicamycin,pentostatin, streptozocin, topotecan, tamoxifen, teniposide,thioguanine, vinblastine, vincristine, and a combination thereof. Inother embodiments, the drug is a chemokine (e.g., CC chemokine, CXCchemokine, C chemokine and CX₃C chemokine) or a cytokine (e.g.,interferone, interleukin, lymphokine, and tumor necrosis factor). Infurther embodiments, the drug is a peptide, preferably a peptide withcytotoxicity effects toward cancer cells. Preferably, the anti-cancerpeptide is selected from the group consisting of leuprolide, goserelin,octreotide, histrelin, abarelix, cetrorelix, degarelix, cilengtide,ATN-161, and IM862.

The term “therapeutically effective amount” as used herein refers to anamount effective, at dosages, and for periods of time necessary, toachieve the desired therapeutically desired result with respect to thetreatment of cancers, including metastatic and/or drug-resistantcancers.

The phrase “pharmaceutically acceptable” refers to molecular entitiesand compositions that are “generally regarded as safe”, e.g., that arephysiologically tolerable and do not typically produce an allergic orsimilar untoward reaction, such as gastric upset, dizziness and thelike, when administered to a human. Preferably, as used herein, the term“pharmaceutically acceptable” means approved by a regulatory agency ofthe Federal or a state government or listed in the U.S. Pharmacopeia orother generally recognized pharmacopeia for use in animals, and moreparticularly in humans.

The term “administered”, “administering” or “administration” are usedinterchangeably herein to refer means either directly administering abi-specific antibody or a composition of the present disclosure.

The term “subject” or “patient” refers to an animal including the humanspecies that is treatable with the compositions and/or methods of thepresent disclosure. The term “subject” or “patient” intended to refer toboth the male and female gender unless one gender is specificallyindicated. Accordingly, the term “subject” or “patient” comprises anymammal which may benefit from treatment of cancer. Examples of a“subject” or “patient” include, but are not limited to, a human, rat,mouse, guinea pig, monkey, pig, goat, cow, horse, dog, cat, bird andfowl. In an exemplary embodiment, the patient is a human.

The term “identical” or “percent identity” as used herein refers to twoor more sequences or subsequences that are the same or have a specifiedpercentage of amino acid residues that are the same, when compared andaligned for maximum correspondence. To determine the percent identity,the sequences are aligned for optimal comparison purposes (e.g., gapscan be introduced in the sequence of a first amino acid sequence foroptimal alignment with a second amino acid sequence). The amino acidresidues at corresponding amino acid positions are then compared. When aposition in the first sequence is occupied by the same amino acidresidue as the corresponding position in the second sequence, then themolecules are identical at that position. The percent identity betweenthe two sequences is a function of the number of identical positionsshared by the sequences (i.e., % identity=number of identicalpositions/total number of positions (e.g., overlapping positions)×100).In certain embodiments, the two sequences are the same length.

The singular forms “a”, “and”, and “the” are used herein to includeplural referents unless the context clearly dictates otherwise.

II. Description of The Invention

Accordingly, it is the first aspect of the present disclosure to providebi-specific antibodies (BsAbs) that convert a non-targeted PEGylatedsubstance to tumor-targeted PEGylated substance and thereby suppress thegrowth of a cancer or blocking the invasion or metastasis of a cancer,including drug-resistant cancer.

1. The Structures of BsAbs of the Present Disclosure

Antibodies belong to the immunoglobulin class of proteins that includesIgG, IgA, IgE, IgM, and IgD. The most abundant immunoglobulin found inserum is IgG, whose schematic structure is illustrated in FIG. 1. TheIgG structure has four chains, two light chains and two heavy chains;each light chain has two domains and each heavy chain has four domains.The antigen-binding site is located in the fragment antigen binding(Fab) region that contains a variable light (VL) and variable heavy (VH)chain domains as well as a constant light (CL) and constant heavy (CH1)domains. The CH2 and CH3 domain region of the heavy chain is calledfragment crystallizable (Fc) region. A full length antibody heavy chainis therefore a polypeptide consisting of, from N-terminus to C-terminus,a VH, a CH1, a hinge region (HR), a CH2, and a CH3; abbreviated asVH-CH1-HR-CH2-CH3. A full length antibody light chain is a polypeptideconsisting in N-terminus to C-terminus direction of a VL and a CL,abbreviated as VL-CL, in which the CL can be κ (kappa) or λ (lambda).The IgG is regarded as a heterotetramer having two heavy chains that areheld together by disulfide bonds (—S—S—) between the CL domain and theCH1 domain and between the hinge regions of the two heavy chains.

As stated above in the “definition” section, the BsAbs refer to Abshaving specificities for at least two different antigens; hence, BsAbsof the present disclosure is a recombinant Ab engineered to containsequences capable of binding to different antigens. Accordingly, variousrecombinant bi-specific antibody formats have been developed in thepresent disclosure, and the schematic structures of these BsAbs areillustrated in FIGS. 2A to 2E.

In some embodiments, the BsAb of the present disclosure is a dimeric,tetravalent bi-specific antibody, in which the two heavy chains of afull length IgG directed to the first antigens are respectively fused tosingle chain variable fragments (e.g., scFv) directed to the secondantigens via peptide linkers (FIG. 2A). The scFv, preferably adisulfide-stabilized scFv, consists of an antibody heavy chain variabledomain (VH) and an antibody light chain variable domain (VL), and alinker; abbreviated as VH-linker-VL.

Alternatively, the BsAb of the present disclosure may be a monomeric,divalent bi-specific antibody, in which a VH-CH1 domain and a lightchain VL-CL domain directed to a first antigen is fused via a peptidelinker to a disulfide stabilized single chain domain directed to asecond antigen (FIG. 2B).

In some embodiments, the BsAb of the present disclosure is a monomeric,divalent bi-specific antibody, in which a disulfide stabilized singlechain domain directed to the first antigen is connected to a monomericantibody directed to a second antigen via a peptide linker (FIG. 2C).

In other embodiments, the BsAb of the present disclosure has a “knobinto hole” structure, in which a knob in the CH3 domain of the firstheavy chain is created by replacing several amino acids with alternativeamino acids, and a hole in the juxtaposed position at the CH3 domain ofthe second heavy chain is created by replacing appropriate amino acidwith alternative ones. In addition, cysteine residues are introduced toform a disulfide bond linkage between the heavy chains. A schematicallypresentation of the “knob into hole” BsAb structure is as depicted inFIG. 2D.

In further embodiments, the “knob in hole” BsAb as depicted in FIG. 2Dis further modified, in which a monomeric antibody heavy chain iscrossovered with its light chain during transcription, and therebycreating a modified antibody heavy chain hetero-polypeptide consistingin N-terminus to C-terminus direction of a VH, a CL, a hinge region(HR), a CH2, and a knob-CH3; abbreviated as VH-CL-HR-CH2-knob-CH3; and amodified antibody light chain hetero-polypeptide consisting inN-terminus to C-terminus direction of a VL and a CH1; abbreviated asVL-CH1. FIG. 2E is a schematic drawing of this modified “knob into hole”BsAb structure, in which one monomeric antibody heavy chain iscrossovered with its light chain, while the other monomeric antibodystructure remains unchanged.

2. Antibody Preparation

Methods for preparing the BsAbs of the present disclosure are describedin the Examples. In order to prepare a humanized BsAb, a non-human(e.g., murine) antibody is prepared and used as a starting material;relevant technology is briefly described in the following section.

2.1 Production of Murine Anti-mPEG Antibody

To produce the desired monoclonal antibodies, animals such as mice, ratsor rabbits are first immunized with mPEG-derivatized proteins (i.e., thePEG molecule has a terminal methoxy group) molecule or PEG-derivatizedproteins (i.e., the PEG molecule has a terminal hydroxyl group) at asuitable dose. Generally, adjuvant and the mPEG- or PEG-derivatizedprotein solution are mixed together when immunizing the animals withmPEG- or PEG-derivatized proteins. Examples of adjuvants useful for thisinvention include Freund's complete adjuvant (FCA), Freund's incompleteadjuvant (FIA), and aluminum hydroxide adjuvant. Immunization isgenerally carried out mainly by intravenous, subcutaneous,intraperitoneal or intramuscular injection of the antigen. Theimmunization interval is not particularly limited. Immunization may becarried out at intervals of several days to several weeks, preferably 2to 3 weeks, for 1 to 10 times, preferably 2 to 5 times. Once antibodytiters in serum samples diluted by 1000 fold reaches 2 or more in theabsorbance level as the result of immunization, the animals are left forabout 1 month

Then, re-immunization is carried out for at least once. Several days,preferably 3 to 5 days, after the final immunization, splenic cells andregional lymph nodes are removed. Blood samples are taken regularlyafter immunization and subject to centrifugation to separate sera. Theresultant sera are then subject to measurement of antibody titers by anysuitable method, which includes, and is not limited to, enzyme linkedimmunosorbent assay (ELISA), enzyme immunoassay (EIA), or radioimmunoassay (RIA). In one preferred example, antibody titers aremeasured by ELISA. Then, final immunization is given to those animalsshowing high antibody titers to mPEG- or PEG-derived protein isoforms.

Antibody-producing cells are prepared from splenic cells and regionallymph nodes or the like of the immunized animals. In the preparation ofantibody-producing cells, it is preferably to remove tissue debris anderythrocytes as much as possible. Commercial erythrocyte remover may beused to this purpose. Alternatively, a buffer ammonium chloride and Trismay be prepared and used.

The thus prepared antibody-producing cells should be immediately fusedwith immortal cells such as myeloma cells to produce hybridoma cells,which semi-eternally continue to proliferate while producing antibodies.

Commonly available cell strains derived from an animal such as a mousemay be used. A preferable cell strain to be used in this inventionshould be those that fuse efficiently, support stable high levelproduction of antibody and are sensitive to HAT selection medium, whichcontains hypoxanthine, thymidine and aminopterin, and should survivethere only when fused with antibody-producing cells. Examples of myelomacells include, but are not limited to, mouse myeloma cell line (such asmyeloma FO cells) and human myeloma cell line (such as Karpas 707H).

Cell fusion is usually carried out by mixing splenic cells or lymph nodecells with a commercial available myeloma cells in the presence of acell-fusion promoter, such as PEG having an average molecular weightfrom about 200 to 20,000 daltons or the like. Alternatively, cell fusionmay be carried out in a commercial cell fusion device utilizing electricstimulation such as electro-fusion. After the fusion, the resultantcells are then diluted and cultured in HAT medium.

Hybridomas of interest are then selected from the fused cells. The fusedcells surviving cultured in HAT medium would form colonies. Thesupernatant of each culture well is then collected and examined for thepresence or absence of antibody titers to mPEG- or PEG-derivatizededproteins. As a method of confirmation, ELISA, EIA or RIA may be used, inwhich CH₃-PEG₇₅₀-NH₂ or NH₂-PEG₃₀₀₀-NH₂ is coated onto the plates andused as a screening criteria.

Once antibody-positive wells are identified, cells are then cultured ina HT medium, which does not contain aminopterin. After culturing for awhile, antibody titers in the culture supernatant are confirmed again.Cells that are finally selected are then subject to cloning to obtainsingle cells. Clones that exhibit high specificity to mPEG- orPEG-derived proteins are selected, and are proliferated to some extentto establish hybridomas.

According to preferred embodiments of the present disclosure, 3hybridomas, E11, 15-2b and 6-3, were selected. The 15-2b hybridomaproduced an anti-mPEG monoclonal antibody that specifically bound toterminal methoxy or hydroxyl group, but not the backbone, of PEG. Bycontrast, the E11 and 6-3 hybridomas, produced anti-PEG backbonemonoclonal antibodies that bound to the backbone, instead of the endmethoxy or hydroxyl group of PEG.

In some embodiments, the anti-mPEG monoclonal antibodies were selectedover the anti-PEG backbone monoclonal antibodies due to spacehomogeneity rendered by anti-mPEG Abs once they were bound withPEGylated nanoparticles. In other embodiments, the anti-PEG backbonemonoclonal antibodies were selected over the anti-mPEG monoclonalantibodies.

The thus produced anti-mPEG or anti-PEG monoclonal antibodies may beisolated or prepared by any known method. For example, antibodies may beprepared from cultured supernatant obtained by culturing hybridomas in amedium with low serum concentration. Alternatively, hybridomas may beinjected into abdominal cavities of animals and the resultant abdominaldropsies are collected to prepare antibodies. Antibodies may be purifiedor isolated by methods that employ affinity column, gel filtrationchromatography, ion exchange chromatography or the like. Any of theseknown methods may be appropriately selected or used in combination.

Alternatively, anti-mPEG or anti-PEG monoclonal antibodies may beproduced by DNA cloning. DNA encoding anti-mPEG or anti-PEG mAbs may beeasily isolated and sequenced by use of conventional procedures, such asusing oliognucleotide probes that are capable of binding specifically togenes encoding the heavy and light chains of the monoclonal antibodies.The hybridoma cells (e.g., E11, 6-3 or 15-2b hybridoma) serve as apreferred source of such DNA.

Once isolated, the DNA may be placed into expression vectors, which arethen transfected into host cells such as E. Coli cells, simian COS cellsor Chinese hamster ovary (CHO) cells or myeloma cells that do notproduce immunoglobulin proteins, to synthesize the desired monoclonalantibodies in the recombinant host cells.

The monoclonal antibodies thus produced and the DNA encoding suchantibodies can then be used to produce chimeric antibodies (e.g.,bi-specific antibodies), humanized antibodies and/or antibody fragmentsderived thereof.

2.2 Production of Humanized Anti-mPEG (15-2) or Anti-PEG (E11 or 6.3)Antibody

The major concern of a non-human origin monoclonal antibody is itsimmunogenicity to the recipient, in some cases, caused dangerousallergic reactions. Most monoclonal antibodies are of murine origin, andhave been found to be immunogenic when injected to human. To reduce theimmunogenicity of anti-mPEG or anti-PEG mAbs of this invention,humanized antibodies are produced by attaching variable domains in theheavy and light chains of murine anti-mPEG or anti-PEG Abs onto theconstant regions of human antibodies.

To create humanized anti-mPEG or anti-PEG antibodies, the DNA encodingsuch antibodies was isolated and sequenced in accordance with methodsdescribed above in section 2.1, and then used to create humanizedconstructs. Detailed production method is set forth in the Examples.

According to preferred embodiments of the present disclosure, CDR(complementary determining region) grafting is employed, in which theCDR regions in the VH and VL genes of a human antibody are replaced withthe appropriate CDR coding segments (such as those DNA segments inanti-mPEG or anti-PEG Abs that code amino acid segments responsible forbinding PEG). The resulting antibodies therefore have variable regionsin which only the CDRs are from the original mouse antibodies, while theframework regions in the VH and VL genes as well as the constant regiongenes (i.e., Cκ or CH1-H-CH2-CH3) are those of human IgG.

In preferred embodiments, the humanized anti-mPEG or anti-PEG Abcomprises a heavy chain variable domain and a light chain variabledomain. Once produced, the humanized anti-mPEG or anti-PEG Abs may bepurified according to standard procedures in the art, includingcross-flow filtration, affinity column chromatography, gel filtrationand the like. It should be understood that the humanized antibodiesshall perform in a manner identical or substantially similar to that ofmurine anti-mPEG Abs. Preferably, the humanized anti-mPEG or anti-PEGAbs (either in the form of Fab or full length IgG) shall be moreadvantages to use in a human subject, as compared to the murine version.In some embodiments, the humanized anti-mPEG Abs are used in theproduction of bi-specific antibodies of the present disclosure. In otherembodiments, the humanized anti-PEG Abs are used in the production ofbi-specific antibodies of the present disclosure.

2.3 Production of Bi-Specific Monoclonal Antibodies (BsAbs)

To produce BsAbs, the humanized anti-mPEG or anti-PEG Abs (either in theform of Fab or a full length IgG) described above in Section 2.2 arefurther linked with antibodies or scFv that bind tumor antigens, so asto confer cancer targeting effect. Detailed production method is setforth in the Examples.

In general, DNA sequences of the above humanized anti-mPEG or anti-PEGAbs including the heavy and light chains of humanized anti-mPEG oranti-PEG sequences are ligated with DNA sequence of a desired antibodyor scFv that binds a tumor antigen via use of a linker, then thechimeric sequence is cloned into an expression vector for transfecting ahost cell, and subsequently purified in accordance with similar stepsdescribed above in section 2.2. The thus produced BsAbs may then be usedto treat cancers or to track the developments of cancers with an aid ofan imaging system.

Accordingly, humanized monomeric and dimeric antibodies are produced,with bi-specificities to both PEGylated molecules and tumor antigens,which include, but are not limited to, TAG72, EGFR, HER2, CD19, andCD20.

In some embodiments, monomeric BsAbs including PEG×EGFR (anti-PEGanti-EGFR), PEG×TAG72 (anti-PEG anti-TAG72), and PEG×HER2 (anti-PEGanti-HER2) are produced, with the anti-PEG portion derived from the hE11Fab fragment. In another embodiment, monomeric h6.3Fab×EGFR (anti-PEGanti-EGFR) and h6.3Fab×CD19 (anti-PEG anti-CD19) are produced, in whichh6.3 Fab, instead of hE11 Fab, is fused with scFv against EGFR or CD19.In a further embodiment, monomeric h15-2b Fab×EGFR scFv (anti-PEGanti-EGFR), h15-2b Fab×HER2 scFv (anti-PEG anti-HER2), are produced, inwhich h15-2b Fab is fused with scFv against EGFR or HER2. In stillfurther embodiments, monomeric h15-2b scFv×CD19 Fab (anti-PEG anti-CD19)and h15-2b scFv×CD20 Fab (anti-PEG anti-CD20) are produced, in whichh15-2b scFv is fused with Fab against CD19 or CD20.

In other embodiments, dimeric BsAbs, including PEG2×EGFR (anti-PEGanti-EGFR), PEG2×TAG72 (anti-PEG anti-TAG72), and PEG2×HER2 (anti-PEGanti-HER2) are produced. Unlike the monomeric BsAb, each dimeric BsAbincludes a full length IgG, with each heavy chain being linked to thescFv that binds a tumor antigen (e.g., TAG 72, EGFR or HER2). Further,monomeric BsAbs of PEG×EGFR, PEG×HER2, and PEG×TAG72 of the presentdisclosure differ from their counterparts in the dimeric forms (i.e.,PEG2×EGFR, PEG2×HER2, and PEG2×TAG72) in that they do not possessHR-CH2-CH3 domains in their respective structures.

In still some other embodiments, “knob in hole” BsAbs are created, inwhich DNA sequences encoding antibody heavy chains, particularly the CH3domains of the two heavy chains, are designed to introduce specific andcomplementary interactions at the interface of the respective CH3domains of the two heavy chains. For example, several amino acids aresubstituted with alternative amino acids in the first heavy chain CH3domain to create a “knob” structure, and several amino acids in thesecond heavy chain CH3 domain are altered to create a “hole” such thatantibody heavy chains expressed from these DNA sequences are unlikely toform a combination of just the first pairs or just the second pairs, butrather the “knob in hole” heavy chain pairs. The knob-in-hole techniqueis well known to those skilled in the art, and can be readily applied informing the BsAbs of the present disclosure. Additionally, the “knob inhole” BsAbs may be further modified by crossing over the antibody heavychain and the antibody light chain, and thereby creating an antibodyheavy chain hetero-polypeptide consisting in N-terminus to C-terminusdirection of a VH, a CL, a hinge region (HR), a CH2, and a knob-CH3;abbreviated as VH-CL-HR-CH2-knob-CH3; and an antibody light chainhetero-polypeptide consisting in N-terminus to C-terminus direction of aVL and a CH1; abbreviated as VL-CH1.

Accordingly, in one specific embodiment, a “knob in hole” anti-mPEG,anti-CD19 BsAb is produced. Specifically, two point mutations, S354C andT366W are introduced into the CH3 region of one h15-2b (anti-mPEG) heavychain to create a knob structure; whereas additional four pointmutations at S349C, T366S, L368A, and Y407V are introduced into the CH3region of one BU12 (anti-CD19) heavy chain to generate a hole structure.In addition to creating the knob and hole structures on respective heavychains, the Bu12-hole heavy chain may be further modified by crossingover with its light chain to generate a hetero heavy chain polypeptideand a hetero light chain polypeptide as described above. Therefore, eacharms of the Y-shape h15-2b knob/Bu12-hole BsAb respectively recognizedifferent antigens, that is, a PEGylated molecule and CD19. In onespecific embodiment, h15-2b knob/HER2-hole BsAb is provided, in whichthe two arms of the Y-shape h15-2b knob/HER2-hole BsAb respectivelyrecognize a PEGylated molecule and HER2.

The components and their respective amino acid sequences of BsAbs of thepresent disclosure are summarized in Tables 1 to 13.

TABLE 1 Amino Acid Sequence of PEG2 × TAG72 Name Amino Acid Sequence SEQID NO Humanized DVVMTQSPLSLPVTLGQPASISCRSSKSIVHSNGNTYLEWFQQR 1 E11 VL-CκPGQSPRRLIYKVSKRMSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQGSHVPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEVTHQGLSSPVTKSFNRGEC HumanizedQVQLVQSGAEVKKPGASVKVSCKASGYTFTTYTMNWVRQAP 2 E11GQGLEWMGYIIPSSGYVDYNQKFKGRVTMTRDTSTSTVYMEL VH-CH1SSLRSEDTAVYYCVRSLDGYFWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKRV HingeEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT 3 CH2-CH3CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK PeptideVDLVTVSSASTGGGSGQLGGGGS 4 Linker Hcc49 dsFvQVQLVQSGAEVKKPGASVKVSCKASGYTFTDHAIHWVRQAPG 5QCLEWMGYFSPGNDDFKYSQKFQGRVTITADKSASTAYMELSSLRSEDTAVYYCARSWIMQYWGQGTLVTVSSGGGGSGGGGSGGGGSDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSYPLTFGCGTKVEIK 6xHis Tag TRHHHHHH 6

TABLE 2 Amino Acid Sequence of PEG2 × EGFR Name Amino Acid Sequence SEQID NO Humanized DVVMTQSPLSLPVTLGQPASISCRSSKSIVHSNGNTYLEWFQQR 1 E11 VL-CκPGQSPRRLIYKVSKRMSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQGSHVPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEVTHQGLSSPVTKSFNRGEC HumanizedQVQLVQSGAEVKKPGASVKVSCKASGYTFTTYTMNWVRQAP 2 E11GQGLEWMGYIIPSSGYVDYNQKFKGRVTMTRDTSTSTVYMEL VH-CH1SSLRSEDTAVYYCVRSLDGYFWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKRV HingeEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT 3 CH2-CH3CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK PeptideVDLVTVSSASTGGGSGQLGGGGS 4 Linker 11F8QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPG 7 anti-EGFRKCLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSV dsFvTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDF AVYYCHQYGSTPLTFGCGTKAEIK6xHis Tag TRHHHHHH 6

TABLE 3 Amino Acid Sequence of PEG2 × HER2 Name Amino Acid Sequence SEQID NO Humanized DVVMTQSPLSLPVTLGQPASISCRSSKSIVHSNGNTYLEWFQQR 1 E11 VL-CκPGQSPRRLIYKVSKRMSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQGSHVPPTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEVTHQGLSSPVTKSFNRGEC HumanizedQVQLVQSGAEVKKPGASVKVSCKASGYTFTTYTMNWVRQAP 2 E11GQGLEWMGYIIPSSGYVDYNQKFKGRVTMTRDTSTSTVYMEL VH-CH1SSLRSEDTAVYYCVRSLDGYFWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKRV HingeEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT 3 CH2-CH3CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK PeptideVDLVTVSSASTGGGSGQLGGGGS 4 Linker C6ML3-9QVQLLQSGAEVKKPGESLKISCKGSGYSFTSYWIAVVVRQMPG 8 anti-HER2KGLEYMGLIYPGDSDTKYSPSFQGQVTISVDKSVSTAYLQWS dsFvSLKPSDSAVYFCARHDVGYCSSSNCAKWPEYFQHWGQGTLVTVSSGGGGSGGGGSGGGGSQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSVVYQQLPGTAPKLLIYDHTNRPAGVPDRFSGSKSGTSASLAISGFRSEDEADYYCASWDYTLSGVVVFGGGT KLTVLG 6xHis Tag TRHHHHHH 6

TABLE 4 Amino Acid Sequence of h6.3Fab × EGFR Name Amino Acid SequenceSEQ ID NO Humanized DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNQMNYLAWYQ 9 6.3VL-Cκ QKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCLQYLSSWTFGGGTKLEIKTYSLSSTLTLSKADYEKHK LYACEVTHQGLSSPVTKSFNRGECHumanized QVQLVQSGSELKKPGASVKVSCKASGYTFKNYGMNWVRQAP 10 6.3GQGLEWMGWINTYTGQPIYANDFKGRFVFSLDTSVSTAYLQIS VH-CH1SLKAEDTAVYYCARDWGPYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVE PKSCDK PeptideVDLVTVSSASTGGGSGQLGGGGS 4 Linker 11F8QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPG 7 anti-EGFRKCLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSV dsFvTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDF AVYYCHQYGSTPLTFGCGTKAEIK6xHis Tag TRHHHHHH 6

TABLE 5 Amino Acid Sequence of h6.3Fab × CD19 Name Amino Acid SequenceSEQ ID NO Humanized DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNQMNYLAWYQ 9 6.3VL-Cκ QKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCLQYLSSWTFGGGTKLEIKTYSLSSTLTLSKADYEKHK LYACEVTHQGLSSPVTKSFNRGECHumanized QVQLVQSGSELKKPGASVKVSCKASGYTFKNYGMNWVRQAP 10 6.3GQGLEWMGWINTYTGQPIYANDFKGRFVFSLDTSVSTAYLQIS VH-CH1SLKAEDTAVYYCARDWGPYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVE PKSCDK PeptideVDLVTVSSASTGGGSGQLGGGGS 4 Linker hBU12QVQLQESGPGLVKPSQTLSLTCTVSGGSISTSGMGVGWIRQHPG 11 dsFvKCLEWIGHIWWDDDKRYNPALKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPRLLIYDTSKLASGIPARFSGSGSGTDFTLTISSLEPEDVA VYYCFQGSVYPFTFGCGTKLEIKR6xHis Tag TRHHHHHH 6

TABLE 6 Amino Acid Sequence of h15-2b Fab × HER2 scFv Name Amino AcidSequence SEQ ID NO Humanized DIQMTQSPSSLSASVGDRVTITCKASQDVNTSVAVVYQQKPGK12 15-2b APKLLIYWASTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATY VL-CκYCLQYINYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEVTHQGLSSPVTKSFNRGEC HumanizedEVQLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNVVVRQAS 13 15-2bGKGLEVVVGEIRSKSNNYATHYAESVKGRFTISRDDSKNTAYL VH-CH1QMNSLKTEDTAVYYCSNRYYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVD KTVERK G-MYC-(G4S)3GEQKLISEEDLGGGGSGGGGSGGGGSQL 14 Linker C6ML3-9QVQLLQSGAEVKKPGESLKISCKGSGYSFTSYWIAVVVRQMPG 15 (Anti-HER2)KGLEYMGLIYPGDSDTKYSPSFQGQVTISVDKSVSTAYLQWS scFvSLKPSDSAVYFCARHDVGYCSSSNCAKWPEYFQHWGQGTLVTVSSGGGGSGGGGSGGGGSQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSVVYQQLPGTAPKLLIYDHTNRPAGVPDRFSGSKSGTSASLAISGFRSEDEADYYCASWDYTLSGVVVFGGGT KLTVLG

TABLE 7 Amino Acid Sequence of h15-2b Fab × EGFR scFv Name Amino AcidSequence SEQ ID NO Humanized DIQMTQSPSSLSASVGDRVTITCKASQDVNTSVAVVYQQKPGK12 15-2b APKLLIYWASTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATY VL-CκYCLQYINYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEVTHQGLSSPVTKSFNRGEC HumanizedEVQLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNVVVRQAS 13 15-2bGKGLEVVVGEIRSKSNNYATHYAESVKGRFTISRDDSKNTAYL VH-CH1QMNSLKTEDTAVYYCSNRYYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVD KTVERK G-MYC-(G4S)3GEQKLISEEDLGGGGSGGGGSGGGGSQL 14 Linker h528DIVMTQSPLSLPVTPGEPASISCRSSQNIVHNNGITYLEVVYLQK 16 (Anti-EGFR)PGQSPQLLIYKVSDRFSGVPDRFSGSGSGTDFTLKISRVEAED scFvVGVYYCFQGSHIPPTFGQGTKVEIKRAGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHVVVRQAPGQGLEWMGNIYPGSGGTNYAEKFKNRVTMTRDTSISTAYMELSRLRSDDTAVYYCARSGGPYFFDYWGQGTLVTVSS

TABLE 8 Amino Acid Sequence of h15-2b scFv × CD19 Fab Name Amino AcidSequence SEQ ID NO Humanized DIQMTQSPSSLSASVGDRVTITCKASQDVNTSVAVVYQQKPGK17 15-2b scFv APKLLIYWASTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQYINYPYTFGQGTKLEIKRGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNVVVRQASGKGLEVVVGEIRSKSNNYATHYAESVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCT NRYYWGQGTLVTVSS G-MYC-(G4S)3GEQKLISEEDLGGGGSGGGGSGGGGSQL 14 Linker hHB12bEVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMNVVVRQAP 18 (Anti-CD19)GKGLEVVVGRIYPGDGDTNYNGKFKGRFTISRDDSKNSLYLQM VH-CH1NSLKTEDTAVYYCARSGFITTVLDFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKRV hHB12bEIVLTQSPDFQSVTPKEKVTITCRASESVDTFGISFMNWFQQK 19 (Anti-CD19)PDQSPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTINSLEAED VL-CκAATYYCQQSKEVPFTFGGGTKVEIKTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEVTHQGLSSPVTKSFN RGEC

TABLE 9 Amino Acid Sequence of h15-2b scFv × CD20 Fab Name Amino AcidSequence SEQ ID NO Humanized DIQMTQSPSSLSASVGDRVTITCKASQDVNTSVAVVYQQKPGK17 15-2b scFv APKLLIYWASTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQYINYPYTFGQGTKLEIKRGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNVVVRQASGKGLEVVVGEIRSKSNNYATHYAESVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCT NRYYWGQGTLVTVSS G-MYC-(G4S)3GEQKLISEEDLGGGGSGGGGSGGGGSQL 14 Linker 2F2MELGLSWIFLLAILKGVQCEVQLVESGGGLVQPGRSLRLSCAA 20 (Anti-CD20)SGFTFNDYAMHVVVRQAPGKGLEVVVSTISWNSGSIGYADSVK VH-CH1GRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKRV2F2 MEAPAQLLFLLLLWLPDTTGEIVLTQSPATLSLSPGERATLSCR 21 (Anti-CD20)ASQSVSSYLAVVYQQKPGQAPRLLIYDASNRATGIPARFSGSG VL-CκSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIKTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEV THQGLSSPVTKSFNRGEC

TABLE 10 Amino Acid Sequence of 15-2b knob/Bu12 hole Name Amino AcidSequence SEQ ID NO 15-2b knob heavy chain HumanizedDIQMTQSPSSLSASVGDRVTITCKASQDVNTSVAWYQQKPGKA 12 15-2bPKLLIYWASTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYC VL-CκLQYINYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEVTHQGLSSPVTKSFNRGEC HumanizedEVQLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASG 13 15-2bKGLEWVGEIRSKSNNYATHYAESVKGRFTISRDDSKNTAYLQM VH-CH1NSLKTEDTAVYYCTNRYYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTK Knob HingeEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT 22 CH2-CH3CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK hBU12EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPR 23 VL-crossoverLLIYDTSKLASGIPARFSGSGSGTDFTLTISSLEPEDVAVYYCFQ CH1GSVYPFTFGQGTKLEIKRSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV hBU12 hole hBU12QVQLQESGPGLVKPSQTLSLTCTVSGGSISTSGMGVGWIRQHPG 24 VH-crossoverKGLEWIGHIWWDDDKRYNPALKSRVTISVDTSKNQFSLKLSSV CκTAADTAVYYCARMELWSYYFDYWGQGTLVTVSSASVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEVTHQGLS SPVTKSFNRGEC holeDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD 25 hinge-CH2-VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT CH3VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK

TABLE 11 Amino Acid Sequence of 15-2b knob/anti-HER2 hole Name AminoAcid Sequence SEQ ID NO 15-2b knob heavy chain HumanizedDIQMTQSPSSLSASVGDRVTITCKASQDVNTSVAWYQQKPGKA 12 15-2bPKLLIYWASTRHTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYC VL-CκLQYINYPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEVTHQGLSSPVTKSFNRGEC HumanizedEVQLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNVVVRQAS 13 15-2bGKGLEVVVGEIRSKSNNYATHYAESVKGRFTISRDDSKNTAYL VH-CH1QMNSLKTEDTAVYYCSNRYYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVD KTVERK Knob HingeEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT 22 CH2-CH3CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK Anti-HER2hole C6ML3-9VL- QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTA 26crossover PKLLIYDHTNRPAGVPDRFSGSKSGTSASLAISGFRSEDEADYY CH1CASWDYTLSGWVFGGGTKLTVLGSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV C6ML3-9QVQLLQSGAEVKKPGESLKISCKGSGYSFTSYWIAWVRQMPGK 27 VH-crossoverGLEYMGLIYPGDSDTKYSPSFQGQVTISVDKSVSTAYLQWSSLK CκPSDSAVYFCARHDVGYCSSSNCAKWPEYFQHWGQGTLVTVSSASVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYA CEVTHQGLSSPVTKSFNRGEC holeDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD 25 hinge-CH2-VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT CH3VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK

TABLE 12 Amino Acid Sequence of h6.3 knob/BU12 hole Name Amino AcidSequence SEQ ID NO h6.3 knob heavy chain HumanizedDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNQMNYLAWYQ 9 6.3 VL-CκQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCLQYLSSWTFGGGTKLEIKTYSLSSTLTLSKADYEKHK LYACEVTHQGLSSPVTKSFNRGECHumanized QVQLVQSGSELKKPGASVKVSCKASGYTFKNYGMNWVRQAP 10 6.3GQGLEWMGWINTYTGQPIYANDFKGRFVFSLDTSVSTAYLQIS VH-CH1SLKAEDTAVYYCARDWGPYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVE PKSCDK Knob HingeEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT 22 CH2-CH3CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK BU12 holehBU12 EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPR 23 VL-crossoverLLIYDTSKLASGIPARFSGSGSGTDFTLTISSLEPEDVAVYYCFQ CH1GSVYPFTFGQGTKLEIKRSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV hBU12QVQLQESGPGLVKPSQTLSLTCTVSGGSISTSGMGVGWIRQHPG 24 VH-crossoverKGLEWIGHIWWDDDKRYNPALKSRVTISVDTSKNQFSLKLSSV CκTAADTAVYYCARMELWSYYFDYWGQGTLVTVSSASVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYACEVTHQGLS SPVTKSFNRGEC holeDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD 25 hinge-CH2-VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT CH3VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK

TABLE 13 Amino Acid Sequence of h6.3 knob/anti-HER2 hole Name Amino AcidSequence SEQ ID NO h6.3 knob heavy chain HumanizedDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNQMNYLAWYQ 9 6.3 VL-CκQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCLQYLSSWTFGGGTKLEIKTYSLSSTLTLSKADYEKHK LYACEVTHQGLSSPVTKSFNRGECHumanized QVQLVQSGSELKKPGASVKVSCKASGYTFKNYGMNWVRQAP 10 6.3GQGLEWMGWINTYTGQPIYANDFKGRFVFSLDTSVSTAYLQIS VH-CH1SLKAEDTAVYYCARDWGPYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVE PKSCDK Knob HingeEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT 22 CH2-CH3CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK Anti-HER2hole C6ML3-9V QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTA 26L-crossover PKLLIYDHTNRPAGVPDRFSGSKSGTSASLAISGFRSEDEADYY CH1CASWDYTLSGWVFGGGTKLTVLGSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV C6ML3-9QVQLLQSGAEVKKPGESLKISCKGSGYSFTSYWIAWVRQMPGK 27 VH-crossoverGLEYMGLIYPGDSDTKYSPSFQGQVTISVDKSVSTAYLQWSSLK CκPSDSAVYFCARHDVGYCSSSNCAKWPEYFQHWGQGTLVTVSSASVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKLYA CEVTHQGLSSPVTKSFNRGEC holeDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD 25 hinge-CH2-VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT CH3VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK

3. Pharmaceutical Kit

It is the second aspect of the present disclosure to provide apharmaceutical kit for treating or imaging cancers, including metastaticand/or drug-resistant cancers. The pharmaceutical kit includes at leasttwo components, the first component being the BsAbs of the presentdisclosure; and the second component being a PEGylated substance, whichincludes a cancer therapeutic agent (e.g., vinca alkaloid) or an imagingagent (e.g., a microbubble containing therein a contrast agent, or aquantum dot) inside the PEGylated substance. Typically, each componentis contained in respective separate container. Preferably, the first andsecond components can be respectively present in the container in a drysolid form or as a suspension in a physiologically acceptable aqueouscarrier. The kit may optionally include a physiologically acceptableaqueous carrier such as a saline for reconstitution of the drycomponents before injection. The two components will be reconstitutedseparately with the respective carriers, then mixed to form an assembly,which is administered to the subject (e.g., by injection).

4. One-Step Method of Targeting and Treating Cancer

Accordingly, it is the third aspect of the present disclosure to providea one-step method of targeting and treating cancers, includingmetastatic and/or drug-resistant cancers. The method takes advantages ofthe pharmaceutical kit described in Section 3, in which the isolatedhumanized anti-PEG bi-specific antibody (BsAbs) as described in Section2 is mixed with a PEGylated substance to form an assembly before beingadministered to the subject. Alternatively, the humanized BsAbs asdescribed in Section 2 is injected to the test subject (e.g., human)first, then followed by the injection of a PEGylated substance (data notshown).

FIG. 3 is a schematic drawing illustrating the one-step targeting andtreating cancer by use of the pharmaceutical kit 300 of the presentdisclosure. The pharmaceutical kit 300 includes a humanized anti-PEGBsAb 310 and a PEGylated substance 320. The humanized anti-PEG BsAb 310is composed of a first antigen binding site 311 that selectively bindsto PEGylated substance 320, which contains a cancer therapeutic agentwithin its structure; and a second antigen binding site 312 thatselectively binds to a target protein, such as a tumor antigen 340. Inthis embodiment, the PEGylated substance 320 is depicted as a liposomeor micelle, and is characterized in having a cancer therapeutic agent321 within the liposome or micelle structure and a plurality of PEGmolecules 322 extended from the surface of the liposome or micelle. Uponbinding to the PEGylated substance 320, the first antigen binding site311 of the BsAb 310 allows the BsAb 310 to orient the second antigenbinding site 312 outward from the surface of the PEGylated substance320, thereby converting the non-targeted PEGylated substance 320 totumor cell-targeted PEGylated substance.

In practice, to achieve one-step targeting and treating purpose, thehumanized anti-PEG BsAb 310 is mixed with the PEGylated substance 320 toform an assembly 330, the assembly 330 is then immediately administered(e.g., injection) to a subject (e.g., a human 360 as depicted in FIG.3).

Accordingly, it is the third aspect of the present disclosure to providea method of treating cancers. The method includes the step of,administering to the subject, the BsAb of the present disclosure and aPEGylated substance containing a cancer therapeutic agent therein, in adose sufficient to inhibit the growth or metastasis of the cancer of thesubject. The dose administered to the subject is from about 0.1 to 50mg/Kg body weight of the subject. In certain embodiments, the dose isadministered to the subject from about 1 to 40 mg/Kg body weight of thesubject, such as 10 to 30 mg/Kg body weight of the subject. The dose canbe administered in a single dose, or alternatively in more than onesmaller doses.

The BsAb of the present disclosure and the PEGylated substance may beadministered to a mammal, preferably human, by any route that mayeffectively transports the cancer therapeutic agent contained in thePEGylated substance to the appropriate or desired site of action, suchas oral, nasal, pulmonary, transdermal, such as passive or iontophoreticdelivery, or parenteral, e.g., rectal, depot, subcutaneous, intravenous,intramuscular, intranasal, intra-cerebella, ophthalmic solution or anointment. It will be appreciated that the dosage of the presentdisclosure will vary from patient to patient not only for the cancertherapeutic agent selected, the route of administration, and the abilityof the BsAb in combination with a PEGylated substance, to elicit adesired response in the patient, but also factors such as disease stateor severity of the condition to be alleviated, age, sex, weight of thepatient, the state of being of the patient, and the severity of thepathological condition being treated, concurrent medication or specialdiets then being followed by the patient, and other factors which thoseskilled in the art will recognize, with the appropriate dosageultimately being at the discretion of the attendant physician. Dosageregimens may be adjusted to provide the improved therapeutic response. Atherapeutically effective amount is also one in which any toxic ordetrimental effects of the cancer therapeutic agent are outweighed bythe therapeutically beneficial effects. Preferably, the BsAb and thePEGylated substance of the present disclosure are administered at adosage and for a time such that the number and/or severity of thesymptoms are decreased.

5. Method of Imaging a Targeted Tissues

The fourth aspect of the present disclosure is to provide a method ofimaging tissues, particularly the cancerous tissues, of a live subject.The method also takes advantages of the pharmaceutical kit described inSection 3, in which the isolated humanized anti-PEG bi-specific antibody(BsAbs) as described in Section 2 is mixed with a PEGylated substance toform an assembly before being administered to the subject.

The method includes the steps of, (a) mixing a first sufficient amountof the humanized BsAb of the present disclosure and a second sufficientamount of a PEGylated quantum dot (PEG-QD) or a PEGylated liposomecontaining a fluorescent dye, to form an assembly; (b) injecting theassembly of the step (a) to a body portion of the subject; and (c)imaging the body portion of the subject by fluorescence imaging,electron spin resonance (ESR) imaging, X-ray imaging, computedtomography (CT), or magnetic resonance imaging (MRI). The PEG-QDincludes a quantum dot nanocrystal selected from the group consisting ofCdHgTe, CdSe, CdSe/ZnS, CdS, CdTe, CdTe/CdS, PbSe and PbS.

The 6.3 antibody comprises the sequence of VL-Cκ domain (SEQ ID NO: 9)and the sequence of VH-CH1 domain (SEQ ID NO: 10), wherein the sequenceof VL-Cκ domain comprises a CDR1 having the sequence of SEQ ID NO: 216;a CDR2 having the sequence of Trp-Ala-Ser; and a CDR3 having thesequence of SEQ ID NO: 217, wherein the sequence of VH-CH1 domaincomprises a CDR1 having the sequence of SEQ ID NO: 218; a CDR2 havingthe sequence of SEQ ID NO: 219; and a CDR3 having the sequence of SEQ IDNO: 220.

The h15-2b antibody comprises the sequence of VL-Cκ domain (SEQ ID NO:12) and the sequence of VH-CH1 domain (SEQ ID NO: 13), wherein thesequence of VL-Cκ domain comprises a CDR1 having the sequence of SEQ IDNO: 221; a CDR2 having the sequence of SEQ ID NO: 222; and a CDR3 havingthe sequence of SEQ ID NO: 223, wherein the sequence of VH-CH1 domaincomprises a CDR1 having the sequence of SEQ ID NO: 224; a CDR2 havingthe sequence of SEQ ID NO: 225; and a CDR3 having the sequence of SEQ IDNO: 226.

The present invention further provides a humanized bi-specific antibodyagainst the terminal methoxy or hydroxyl group of polyethylene glycol(PEG) and a target ligand on a cancer cell, comprising, a first antigenbinding site that binds to the PEG, wherein the first antigen bindingsite comprises a first VL-Cκ domain and a first VH-CH1 domain; and asecond antigen binding site that binds to the target ligand on thecancer cell, wherein, the first VL-Cκ domain comprises a CDR1 having thesequence of SEQ ID NO: 221; a CDR2 having the sequence of SEQ ID NO:222; and a CDR3 having the sequence of SEQ ID NO: 223; and the firstVH-CH1 domain comprises a CDR1 having the sequence of SEQ ID NO: 224; aCDR2 having the sequence of SEQ ID NO: 225; and a CDR3 having thesequence of SEQ ID NO: 226.

In one embodiment, the first VL-Cκ domain has the sequence of SEQ ID NO:12, and the first VH-CH1 domain has the sequence of SEQ ID NO: 13.

In another embodiment, the first antigen binding site further comprisesa Knob Hinge CH2-CH3 domain connecting to the first VH-CH1 domain,wherein the Knob Hinge CH2-CH3 domain has the sequence of SEQ ID NO: 22.

In one embodiment, the first antigen binding site and the second antigenbinding site are Fab or single chain variable fragment (scFv).

In another embodiment, the target ligandis EGFR, HER2, TAG-72, CD19 orCD20.

The present invention will now be described more specifically withreference to the following embodiments, which are provided for thepurpose of demonstration rather than limitation.

EXAMPLES

Materials and Methods.

Cells and Animals

Breast cancer cell line MCF-7, human T lymphocyte cell line Jurkat,ovarian cancer cell line OVCAR-3, epidermoid carcinoma cell line A431(EGFR⁺) (ATCC CRL1555), B lymphocyte cell line Raji (CD19⁺) (ATCCCCL86), malignant melanoma cell line A-375, 293FT cells,B-lymphoblastoid cell line Ramos (CD19⁺) (ATCC CRL-1596), SW480 (EGFR⁺),SW620 human colon carcinoma cells, human breast adenocarcinoma cell lineSKBR3 (HER2⁺), human breast adenocarcinoma cell line MDA-MB-468, BALB3T3 cells, and GP2-293 retrovirus packaging cells were used in thepresent disclosure. In general, cells were cultured in Dulbecco'smodified Eagle's medium (Sigma, St Louis, Mo., USA) supplemented with10% fetal calf serum (HyClone, Logan, Utah), 100 U/mL penicillin and 100μg/mL streptomycin at 37° C. in an atmosphere of 5% CO₂ in air. A431,Raji and Ramos cells were grown in RPMI-1640 containing the samesupplements but with 10% bovine serum source.

Female BALB/c nude mice (6-8 weeks old) were obtained from the NationalLaboratory Animal Center, Taipei, Taiwan. All animal experiments wereperformed in accordance with institutional guidelines and approved bythe Laboratory Animal Facility and Pathology Core Committee of IBMS,Academia Sinica.

Generating Murine Anti-PEG Antibodies (Abs)

Hybridoma cells secreting anti-PEG Ab were generated by immunizingfemale BALB/c mice with mPEG-derived proteins or PEG-derived proteins asdescribed previously (Su et al., Bioconjugate Chemistry (2010) 21(7),1264-1270). The hybridomas were then screened by ELISA. Specifically,96-well plates were coated with 1 μg/well CH3-PEG₇₅₀-NH2,NH2-PEG₃₀₀₀-NH2 (Sigma-Aldrich), or CH3-PEG₅₀₀₀-NH2 in 5 μL/well 0.1MNaHCO₃/Na₂CO₃ for 3 hr at 37° C. and then blocked with 200 μL/welldilution buffer (2% skim mile in PBS) at 4° C. overnight. Gradedconcentrations of antibodies in 50 μL 2% skim milk were added to platesat room temperature for 1 hr. The plates were washed with PBS-T (PBScontaining 0.05% Tween-20) 3 times and with PBS 2 times. HRP-conjugatedgoat anti-mouse IgMμchain (2 μg/mL) or HRP-conjugated donkey antimouseIgG Fc (2 μg/mL) in 50 μL dilution buffer were added for 1 hr. Theplates were washed and peroxidase activity was measured by adding 100μL/well TMB substrate solution (BioLegend, San Diego, Calif.) for 30 minat room temperature. After adding stop buffer (2N H₂SO₄, 50 μL/well),the absorbance (405 nm) were read. Selected hybridomas were cloned threetimes by limiting dilution in 96-well plates containing thymocyte feedercells in HT medium (Sigma-Aldrich) supplemented with 15% fetal calfserum (Hyclone), and then three hybridoma cells, E11, 6-3, and 15-2bwere produced, in which E11 and 6-3 secreted anti-PEG backbone Abs,whereas 15-2b secreted anti-mPEG Abs.

Construction of DNA Plasmids for PEG2×EGFR, PEG2×TAG72, PEG2×HER2,h6.3Fab×EGFR, and h6.3Fab×CD19

To generate the anti-PEG Fab or IgG based BsAbs, the mouse V_(L) andV_(H) domains of the anti-PEG antibodies were cloned from cDNArespectively prepared from the E11, 6-3, and 15-2b hybridoma cells. Thehumanized V_(L) and V_(H) domains of the anti-PEG (hE11, h6-3) andanti-mPEG (h15-2b) antibodies, generated by grafting the DNA sequencescoding the complementarity-determining regions (CDRs) of the light andheavy chain variable region genes of E11, h6-3 and 15-25 into theframework regions of human IgG VL and VH genes, then were fused with theDNA sequence encoding the remaining human IgG1 constant region genes.

The Cκ, CH₁, and partial CH₁-hinge-CH₂—CH₃ (Fc), constant domains ofhuman IgG₁ were cloned from extracted human PBMC cDNA by using theprimers in Table 14.

TABLE 14 Primers For Cloning Human CH₁, Cκ and F_(c) Fragments SEQ NameSequence (5′-3′) ID NO CH₁ ctggtcaccgtctcctcagcctccaccaagggaccatcg 28(forward) gtcgactttgtcacaagatttgggc 29 (reverse) Cκaccaaggtggagatcaaacggactgtggctgcaccatct 30 (forward)ctcgaggcactctcccctgttgaagc 31 (reverse) F_(c)ggtggacaagagagttgagcccaaatcttgtgac 32 (forward)caattgtccactgccacccccgcttga 33 (reverse)

The humanized variable domains (V_(L) or V_(H)) and human antibodyconstant domains (Cκ, CH₁, or Hinge-CH₂—CH₃) were joined by overlap PCR.To this aim, all the humanized V_(L) fragments were amplified by PCR tointroduce a partial Cκ fragment at the C-terminus using primers in Table15.

TABLE 15 Primers For Cloning the V_(L) Domains of humanized E11, 6-3,15-2b anti-PEG fragments Name Sequence (5′-3′) SEQ ID NO hE11V_(L)ggcccagccggccgatgttgtgatgactcagtc 34 (forward) hE11V_(L)-partialgtgcagccacagtccgtttgatctccaccttggtc 35 Cκ (reverse) h6-3V_(L)(forward)ggcccagccggcc gacatcgtgatgacccag 36 h6-3V_(L)-partial Cκgtgcagccacagtccgtttgatttccaccttggtc 37 (reverse) h15-2bV_(L)ggcccagccggccgacatccagatgacccag 38 (forward) h15-2bV_(L)-partialgtgcagccacagtccgtttgatctccagcttggtc 39 Cκ (reverse)

The V_(L)-partial Cκ and Cκ fragments were again joined by overlap PCRto generate V_(L)-Cκ fragments using the forward primers of V_(L)domains and the Cκ reverse primer as shown above in Tables 14 and 15.

Likewise, all the humanized V_(H) fragments were amplified by PCR tointroducing partial CH₁ fragment at the C-terminus using primers shownin Table 16.

TABLE 16 Primers For Cloning the V_(H) Domains of humanized E11, 6-3,15-2b anti-PEG Fragments Name Sequence (5′-3′) SEQ ID NO hE11V_(H)agatctcaggtgcagctggtgcag 40 (forward) hE11V_(H)-partialtcccttggtggaggctgaggagacggtgaccaggg 41 CH₁ (reverse) h6-3V_(L)Hagatctcaggtgcagctggtgcaatc 42 (forward) h6-3V_(H)-partial CH₁gtcccttggtggaggctgaggagacggtgaccag 43 (reverse) h15-2bV_(H)agatctgaggtgcagctggtggag 44 (forward) h15-2bV_(H)-partialgcccttggtggaggctgaggagacggtgaccaggg 45 CH₁ (reverse)

The V_(H)-partial CH₁, CH₁ and Fc fragments were joined by overlap PCRto generate V_(H)-CH₁ or V_(H)-CH₁-hinge-CH₂—CH₃ fragments using theforward primers of V_(H) domains, and the CH1 and Fc reverse primers asindicated above in Tables 14 and 16.

The hBU12 dsFv DNA fragment was synthesized by assembly PCR based on theV_(H) and V_(L) sequences of hBU12 described in U.S. Pat. No. 7,968,687B2, the entirety of which is incorporated herein by reference. PCR wascarried out as follows: 95° C. for 3 min; 10 cycles at 95° C. for 30 s,63 to 53° C. touchdown for 1 min (decrease 1° C. every cycles), 72° C.for 1 min; 25 cycles at 95° C. for 30 s, 53° C. for 1 min, 72° C. for 1min; 72° C. for 10 min. The V_(H) and V_(L) fragments were joined andamplified using P1 and P22 primers described in Table 17. The 11F8 dsFvDNA fragment was synthesized by assembly PCR based on the V_(H) andV_(L) sequences of 11F8 described in EP2332990 A1, the entirety of whichis incorporated herein by reference. PCR was carried out as describedabove. The V_(H) and V_(L) fragments were assembled by assembly PCRusing primers P23 to P34 and primers P35 to P44, respectively describedin Table 18. The hCC49 scFv and DNS scFv DNA fragments were amplified byPCR using the primers as described in our previous studies (K C Chen etal., Bioconjugate Chemistry 22: 938-948, 2011). The production ofC6ML3-9 dsFv plasmid was described in EP2258726A1. We next generatedSaII-linker-MfeI-hBU12 scdsFv-MluI-6×His-ClaI by PCR using primers setforth in Table 19; whereas MfeI-linker-11F8 dsFv-MluI, MfeI-linker-DNSdsFv-MluI and MfeI-linker-hCC49 dsFv-MluI are generated by PCR usingprimers as described in Table 20.

TABLE 17 Primers For Cloning hBU12 dsFv Primer SEQ ID name PrimerSequence (5′-xxxxxxx-3′) NO P1CAATTGCAGGTTCAGCTGCAAGAGTCTGGCCCTGGGTTGGTTAAGCCC 46 P2CAGTACAAGTCAGACTGAGGGTCTGGGAGGGCTTAACCAACCCAGGGCC 47 P3CAGTCTGACTTGTACTGTGTCTGGGGGTTCAATCAGCACTTCTGGTATG 48 P4CTGGGTGCTGCCTAATCCAGCCTACACCCATACCAGAAGTGCTGATTG 49 P5GGATTAGGCAGCACCCAGGGAAGTGTCTGGAGTGGATTGGACACATTTGG 50 P6AACAGTAATAGACAGCAACATCCTCTGGCTCCAGGCTGCTGATTGTG 51 P7CAAGAGATATAACCCAGCCCTGAAGAGCAGAGTGACAATCTCTGTGGATAC 52 P8GACAGCTTGAGGCTAAACTGGTTCTTGGAGGTATCCACAGAGATTGTCAC 53 P9GTTTAGCCTCAAGCTGTCCAGTGTGACAGCTGCAGATACTGCTGTCTAC 54 P10AAACAGTAATAGACAGCAACATCCTCTGGCTCCAGGCTGCTGATTGTG 55 P11GGAACTTTGGTCCTACTATTTTGACTACTGGGGCCAAGGCACCCTTG 56 P12GCCCCCTGACCCGCCACCTCCTGAGGAGACTGTGACAAGGGTGCCTTGGCCCC 57 P13GGTGGATCGGGGGGTGGCGGATCTGAAATTGTTCTCACCCAGTCTCCAGCAAC 58 P14CAGGGTAGCCCTTTCCCCTGGAGAGAGAGACAGGGTTGCTGGAGACTGGGTG 59 P15GGGGAAAGGGCTACCCTGAGCTGCAGTGCCAGCTCAAGTGTAAGTTACATGC 60 P16CTGGGAGCCTGCCCTGGCTTCTGCTGGTACCAGTGCATGTAACTTACACTTG 61 P17GCCAGGGCAGGCTCCCAGACTCCTGATTTATGACACATCCAAACTGGCTTC 62 P18CCAGACCCACTGCCACTGAACCTTGCTGGAATACCAGAAGCCAGTTTGGATG 63 P19CAGTGGCAGTGGGTCTGGAACAGATTTTACACTCACAATCAGCAGCCTGG 64 P20GAAAACAGTAATAGACAGCAACATCCTCTGGCTCCAGGCTGCTGATTGTG 65 P21GCTGTCTATTACTGTTTTCAGGGGAGTGTATACCCATTCACTTTTGGC 66 P22ACGCGTTCTTTTGATTTCCAACTTTGTCCCGCAGCCAAAAGTGAATGGG 67

TABLE 18 Primers For Cloning 11F8 dsFv SEQ ID Primer name primersequence (5′-xxxxxxx-3′) NO P23GTCGACCAATTGGGAGGTGGCGGATCCCAGGTGCAGCTGCAGGAGTCGGG 68 P24ACAGGGTCTGTGAAGGCTTCACCAGTCCTGGGCCCGACTCCTGCAGCTGC 69 P25AGCCTTCACAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAG 70 P26GGCGGATCCAACTCCAGTAGTAATCACCACTGCTGATGGAGCCACCAGAGAC 71 P27ACTGGAGTTGGATCCGCCAGCCCCCAGGGAAGTGCCTGGAGTGGATTGGG 72 P28GGTTGTAGTCGGTGCTCCCACTGTAATAGATGTACCCAATCCACTCCAGGCA 73 P29TGGGAGCACCGACTACAACCCGTCCCTCAAGAGTCGAGTCACCATGTCCGTA 74 P30ACCTTCAGGGAAAACTGATTCTTGGACGTGTCTACGGACATGGTGACTCG 75 P31TCAGTTTTCCCTGAAGGTCAACTCTGTGACCGCCGCAGACACGGCTGTGT 76 P32CCCCACTCCAAAAATCGACACTCTCGCACAGTAATACACAGCCGTGTCTGCGG 77 P33TCGATTTTTGGAGTGGGGACATTTGACTACTGGGGCCAGGGCACCCTGGT 78 P34ACCGCCCCCTGACCCGCCACCTCCGCTTGAGACGGTGACCAGGGTGCCCTGGCC 79 P35GGATCGGGGGGTGGCGGATCTGAAATTGTGATGACACAGTCTCCAGCCACCCTGTC 80 P36GCAGGAGAGGGTGGCTCTTTCCCCTGGAGACAAAGACAGGGTGGCTGGAGAC 81 P37AGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTA 82 P38AGCCTGGCCAGGTTTCTGTTGGTACCAGGCTAAGTAGCTGCTAACACT 83 P39CAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAG 84 P40ACTGCCACTGAACCTGGCTGGGATGCCAGTGGCCCTGTTGGATGCATCATAG 85 P41GCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAG 86 P42AATACACTGCAAAATCTTCAGGCTCTAGGCTGCTGATGGTGAGAGTGAAG 87 P43GAAGATTTTGCAGTGTATTACTGTCACCAGTATGGTAGCACACCTCTCACTT 88 P44ACGCGTTTTGATCTCCGCCTTGGTCCCGCAGCCGAAAGTGAGAGGTGTGCTA 89

TABLE 19 Primers For Cloning Sall-linker-Mfel-hBU12 scFv-Mlul-6xHis-ClalSEQ ID Name Sequence (5′-3′) NO linker-Mfel-hBU12gtggtggttcaggacaattgggaggtggcggatcccaggttcagctgcaagag 90 V_(H) (forward)Sall-linker-Mfel-hBU12gtcgacctggtcaccgtctcctcagcctccaccggtggtggttcaggacaat 91 V_(H) (forward)hBU12V_(L)-Mlul- atcgatttaatgatgatgatgatgatgacgcgttatttgatttccaactttg 926xHis-Clal (reverse)

TABLE 20 Primers For Cloning Mfel-linker-11F8 dsFv-Mlul, Mfel-linker-DNSdsFv-Mlul and Mfel-linker-hCC49 dsFv-Mlul Name Sequence (5′-3′) SEQ IDNO Mfel-hl1F8 V_(H) caattgggaggtggcggatcccaggtgcagctgcaggag 93 (forward)Mlul-11F8V_(L) acgcgttttgatctccgccttggtc 94 (reverse) Mfel-DNSV_(H)caattgggaggtggcggatccagtgaagtgaagcttgag 95 (forward) Mlul-DNSV_(L)acgcgtccgttttatttccaactt 96 (reverse) Mfel-hCC49V_(H)caattgggaggtggcggatcccaggtgcagctggtgcag 97 (forward) Mlul-hCC49V_(L)acgcgttttgatctccaccttggtc 98 (reverse)

The pLNCX-SfiI-mAGP3 V_(L)-Cκ-XhoI-F2A-BgIII-mAGP3 VH-CH₁-SaII-eB7-ClaIplasmid was used as template for further sub-cloning. TheseSfiI-V_(L)-Cκ-XhoI or BgIII-VH-CH₁-SaII orBgIII-VH-CH₁-hinge-CH₂—CH₃-SaII fragments were sub-cloned into thetemplate DNA plasmid described above by digesting with properrestriction enzyme to generate pLNCX-SfiI-anti-PEGV_(L)-Cκ-XhoI-F2A-BgIII-anti-PEG V_(H)-CH₁-SaII-eB7-ClaIorpLNCX-SfiI-anti-PEGV_(L)-Cκ-XhoI-F2A-BglII-anti-PEGV_(H)-CH1-hinge-CH2-CH3-SaII-eB7-ClaIplasmids. Furthermore, the single chain variable fragments (scFv orscdsFv) were sub-cloned into these plasmids by using SaII and ClaI orfollowed by MfeI and ClaI enzyme digestion.

Construction of DNA Plasmids for 15-2b Knob/Bu12 Hole,15-2Bknob/Anti-HER2 Hole, h6.3 Knob/Bu12 Hole, and h6.3 Knob/Anti-HER2Hole

To construct the knob into hole BsAbs, V_(H)-CH₁ of h15-2b or h6-3 wasfused with the modified human IgG₁ CH₂—CH₃ domain to form the heavychain of h15-2b-knob or h6-3-knob by assembly PCR. The heavy chainsequence, which is followed by a sequence derived from furin-2A (F2A)and the light chain sequence of h15-2b or h6-3, was cloned into lentivalvector pLKOAS3W-hyg (RNAi core, Academia Sinica, Taipei, Taiwan) by useof NheI and PmeI restriction sites. We adopted the immunoglobulin domaincrossover approach, alone with modifications of the locations of theC_(H)1 and hinge regions, to generate BU12-hole and α-Her2-hole. Inbrief, V_(H)-partial CH₁-Cκ-partial hinge, with a human influenza virushemagglutinin (HA) tag protein fused at the N terminal of the heavychain was fused with human IgG1 CH₂—CH₃ domain to form the new heavychain. V_(L)-CH1-partial hinge sequences of α-Her2 Ab or BU12 wereconnected with the new heavy chain sequences by a F2A sequence andcloned into lentiviral vector pLKOAS3W-pur (RNAi core, Academia Sinica,Taipei, Taiwan) by use of SfiI and PmeI restriction sites. Primers usedfor cloning were as described in Table 21.

TABLE 21 Primers For Cloning knob into hole BsAbs SEQ ID Name Sequence(5′-3′) NO 15-2b-knob: V_(L)-C_(κ) agatctgacatccagatgacccag 99 (forward)tatcgatgtttaaacctagcactctcccctgttgaa 100 (reverse) V_(H)-CH₁ggcccagccggccgaggtgcagctggtggag 101 (forward) aagttttttgtcgaccgtgg 102(reverse) huIgG1-upper hinge gacaaaactcacacatgcccaccgtgc 103 (forward)CH₁-partical hinge gcatgtgtgagttttgtcacaagatttgggctcaac 104 (reverse)CH₃ ctcgagtttacccggagacaggga 105 (reverse) h6-3-knob: 104 V_(L)-C_(κ)agatctgacatcgtgatgacccagtctc 106 (forward)tatcgatgtttaaacctagcactctcccctgttgaa 107 (reverse) V_(H)-CH₁caggtgcagctggtgcaat 108 (forward) aactctcttgtccaccttgg 109 (reverse)BU12-hole: V_(H)-C_(κ)-partial hinge agccggcccaggttcagctgcaagagtctggc110 (forward) gcatgtgtgagttttgtcacactctcccctgttgaagct 111 (reverse)V_(L)-partial gaaattgttctcacccagtctcc 112 V_(H)-CH₁-upperHinge (forward)ttaacaagatttgggctcaac 113 (reverse) partial V_(L)-hCH₁gttggaaatcaaaagatcctcagcctccaccaagggcccatcg 114 (forward) α-Her2-hole:V_(H) ggcccagccggcccaggtgcagctgttgcagtctggg 115 (forward)V_(H)-C_(κ)-partial hinge aggtgcagctgttgcagtctggg 116 (forward)gcatgtgtgagttttgtcacactctcccctgttgaagct 117 (reverse) V_(L)-partialV_(H) ctgaccgtcctaggttcctcagcctccaccaagggcccatcg 118 (forward)acctaggacggtcagcttggtcccgccgccgaacacccagcccga 119 (reverse) V_(L)ctgccagatctcagtctgtgttgacgcag 120 (forward)acctaggacggtcagcttggtcccgccgccgaacacccagcccga 121 (reverse) CH₁-upperhinge ttaacaagatttgggctcaac 122 (reverse)

Constructing DNA Plasmids for 15-2b Fab×HER2 scFv, 15-2b Fab×EGFR scFv,15-2b scFv×CD19 Fab, and 15-2b scFv×CD20 Fab

The V_(L)-Cκ and V_(H)-CH1 domains of the anti-mPEG antibody were clonedfrom the cDNA of the 15-2b hybridoma and humanized as describedpreviously (Chuang K-H et al., J. Nucl. Med. 2010 (51): 933-941). Thehumanized anti-mPEG V_(L) and V_(H) segments were synthesized byassembly polymerase chain reaction (PCR) and were subcloned intoretroviral vector pLNCX-anti-PEG-eB7) in the unique BgIII, SaII, SfiI,and XhoI restriction enzyme sites, respectively. Primers for cloning15-2b Fab sequence are given in Table 22. The human anti-EGFR scFv wascloned based on the h528Fv DNA sequence (Makabe et al., (2008) J. Biol.Chem, 283, 1156-1166). Therefore, h528Fv DNA sequence was generated byassembly PCR. Primers used in the cloning of anti-EGFR V_(H) and V_(L)are given in Table 23. Then, using Mfe-ahEGFR VL primer, ahEGFRV_(L)-(G4S)2 primer, (G4S)2-ahEGFR V_(H) primer and ahEGFRV_(H)-stop-Cal primer to create human anti-EGFR scFv, which contained amyc tag and fifteen amino acid (GGGGS)3 flexible linker in front of thesequence.

A human anti-HER2 scFv and anti-DNS scFv were cloned from the pBub-YCMCplasmid (Shahied et al., (2004) J. Biol. Chem. 279, 53907-53914) andpLNCX-DNS-B7 (Chuang et al., (2006) Bioconjugate Chemistry 17, 707-714),respectively. Primers for cloning human anti-HER2 scFv and anti-DNS scFvare given in Tables 24 and 25, respectively. A myc tag and fifteen aminoacid (GGGGS)3 flexible linker was placed between the anti-mPEG Fab andscFv genes to generate pLNCX-PEG×EGFR, pLNCX-PEG×HER2 and pLNCX-PEG×DNSplasmids by using SaII and Call restriction enzyme sites.

TABLE 22 Primers For Cloning h15-2b Fab Sequence SEQ ID Name of PrimerSequence NO h15-2b VH-CH1 h15-2b Bgl-VH-15′-gaagatctgaggtgcagctggtggagtctgggggaggcttggtccag-3′ 123 (forward)h15-2b VH-2 5′-agaggctgcacaggagagtttcagggaccccccaggctggaccaagcctcc-3′124 (reverse) h15-2b VH-35′-tcctgtgcagcctctgggttcaccttcagtaactactggatgaactgggtc-3′ 125 (forward)h15-2b VH-4 5′-gccaacccactccagccctttcccggaagcctggcggacccagttcatcca-3′126 (reverse) h15-2b VH-55′-ctggagtgggttggcgaaattagatcgaaatctaataattatgcgacacat-3′ 127 (forward)h15-2b VH-6 5′-ggagatggtgaacctccctttcacagactccgcataatgtgtcgcataatt-3′128 (reverse) h15-2b VH-75′-aggttcaccatctccagagatgattcaaagaacacggcgtatctgcaaatg-3′ 129 (forward)h15-2b VH-8 5′-gtaatacacggccgtgtcctcggttttcaggctgttcatttgcagatacgc-3′130 (reverse) h15-2b VH-95′-acggccgtgtattactgttccaacagatactactggggccaaggaaccctg-3′ 131 (T93S)(forward) h15-2b VH-105′-acctttggtggaggctgaggagacggtgaccagggttccttggcc-3′ 132 (reverse) homo3′ IgG2 5′-acgcgtcgactttgcgctcaactgtctt-3′ 133 CH1-Sall (reverse) h15-2bVL-Cκ h15-2b sfi-VL-1 5′-tgctggggcccagccggccgacatccagatgacccagtctcca-3′134 (forward) h15-2b VL-25′-ggtgactctgtctcctacagatgcagacagggaggatggagactgggtcat-3′ 135 (reverse)h15-2b VL-3 5′-ggagacagagtcaccatcacttgcaaggccagtcaggatgtaaatacttct-3′136 (forward) h15-2b VL-45′-aggggctttccctggtttctgctgataccaggctacagaagtatttacatc-3′ 137 (reverse)h15-2b VL-5 5′-ccagggaaagcccctaagctcctgatctactgggcatccacccggcacact-3′138 (forward) h15-2b VL-65′-cccagatccacttccactgaaccttgatgggaccccagtgtgccgggtgga-3′ 139 (reverse)h15-2b VL-7 5′-ggaagtggatctgggacagattttactttcaccatcagcagcctgcagcct-3′140 (forward) h15-2b VL-85′-gatatattgcagacagtaatatgttgcaatatcttcaggctgcaggctgct-3′ 141 (reverse)h15-2b VL-9 5′-tgtctgcaatatatcaactatccgtacacgtttggccaggggaccaagctg-3′142 (forward) h15-2b VL-105′-tggtgcagccacagtccgtttgatctccagcttggtcccctg-3′ 143 (reverse) homo 3′5′-ccgctcgaggcactctcccctgttgaagctctttgtgacgggcgagctcaggccctg- 144Cκcys-Xhol 3′ (reverse)

TABLE 23 Primers for the cloning of h528 (Anti-EGFR) scFv SEQ ID Name ofPrimer Sequence NO h528VH015′-caggtgcaactggttcagagcggcgcggaagtgaaaaagccgggcgcgtcggtt-3′ 145(forward) h528VH025′-aaaggtatagcctgaggctttgcagctcactttaaccgacgcgcccgg-3′ 146 (reverse)h528VH03 5′-tcaggctatacctttacgagctactggatgcattgggtgcgccaggcc-3′ 147(forward) h528VH045′-aatgttacccatccattccaggccctgacccggggcctggcgcaccca-3′ 148 (reverse)h528VH05 5′-tggatgggtaacatttatccgggcagcggtggcaccaactatgcggaa-3′ 149(forward) h528VH065′-atcacgcgtcatggtcacgcggttcttaaatttttccgcatagttggt-3′ 150 (reverse)h528VH07 5′-accatgacgcgtgataccagcatttcgacggcctatatggaactgagc-3′ 151(forward) h528VH085′-gtaatacacggcggtgtcatcgctacgcaggcggctcagttccatata-3′ 152 (reverse)h528VH09 5′-accgccgtgtattactgcgcgcgcagtggcggtccgtattttttcgat-3′ 153(forward) h528VH105′-cgagctcacggtaaccagcgtaccctggccccagtaatcgaaaaaatacgg-3′ 154 (reverse)(G4S)2-ahEGFR 5′-ggcggtggtgggtcgggtggcggcggatctcaggtgcaactggtt-3′ 155 VH(forward) ahEGFR 5′-ccatcgatttacgagctcacggtaac-3′ 156 VH-stop-Cal(reverse) h528VL015′-gatattgtgatgacccagagcccgctgagcctgccggtgaccccaggc-3′ 157 (forward)h528VL02 5′-ctgcgagctgcggcagctaatcgacgccggttcgcctggggtcaccgg-3′ 158(reverse) h528VL035′-tgccgcagctcgcagaacatcgtgcataataacggcattacctatctg-3′ 159 (forward)h528VL04 5′-cgggctttggcccggtttctgcagataccattccagataggtaatgcc-3′ 160(reverse) h528VL055′-ccgggccaaagcccgcagctgttaatttataaagtgagcgatcgcttt-3′ 161 (forward)h528VL06 5′-accgctgcccgaaaagcgatccggcacgccgctaaagcgatcgctcac-3′ 162(reverse) h528VL075′-ttttcgggcagcggtagtggcaccgattttacgctgaaaattagccgc-3′ 163 (forward)h528VL08 5′-gcagtaatacacgccaacatcctccgcttccacgcggctaattttcag-3′ 164(reverse) h528VL095′-ggcgtgtattactgctttcagggcagccatatcccgccaacctttggc-3′ 165 (forward)h528VL10 5′-cgcgcgtttaatttccactttggtgccttggccaaaggttggcgg-3′ 166(reverse) Mfe-ahEGFR VL 5′-caattggatattgtgatgacccag-3′ 167 (forward)ahEGFR 5′-cgacccaccaccgcccgagccaccgccacccgcgcgtttaatttc-3′ 168 VL-(G4S)2(reverse)

TABLE 24 Primers for the cloning of C6ML3-9 (Anti-HER2) scFv SEQ Name ofID Primer Sequence NO Sal-G- 5′-acgcgtcgacggggaacaaaaactcatctcagaa 169myc-G4S gaggatctgggaggcggtggcagt-3′ (forward) G2S-5′-ggtggcagtggtggtggtggatcaggaggtggcg 170 G4SX2-gatcccaattgcaggtgcagctg-3′ Mfel (forward) Her25′-atcgattcaacctaggacggtcagctt-3′ 171 scFv- stop-Clal (reverse)

TABLE 25 Primers for the cloning of h15-2b scFv SEQ Name of ID PrimerSequence NO mfe1- 5′-caattggacatccagatgacccagtctcca-3′ 172 h15-2bVL(forward) h15-2bscFv- 5′-cccctgcaggcatcgatttatgaggagac 173 Clal-Sbflggtgac-3′ (reverse)

Primers for cloning Human anti-CD19 VH and VL are given in Tables 26.The cloned human anti-CD19 VH and VL sequences (Table 13) were thenfused with DNA sequence of h15-2b scFv to generate DNA construct forexpressing BsAbs of PEG×CD19. Similarly, human anti-CD20 VH and VL werecloned by primers given in Table 27 and the cloned human anti-CD20 andanti-CD22 sequences were then fused with DNA sequence of h15-2b scFv toproduce constructs for expressing BsAbs of PEG×CD20 and PEG×CD22,respectively.

TABLE 26 Primers for the cloning of hHB12b (Anti-CD19) VL and VH SEQ IDName of Primer Sequence NO hHB12b VL Nael-X + hHB12bVL-15′-gccggccgagatcgtgctgacccagagccccgacttccagagc-3′ 174 (forward)hHB12bVL-2 5′-ctctgcaggtgatggtcaccttctccttgggggtcacgctctggaagtcgggg-3′175 (reverse) hHB12bVL-35′-gtgaccatcacctgcagagccagcgagagcgtggacaccttcggcatcagcttc-3′ 176(forward) hHB12bVL-45′-gctctggtcgggcttctgctggaaccagttcatgaagctgatgccgaaggtg-3′ 177 (reverse)hHB12bVL-5 5′-gaagcccgaccagagccccaagctgctgatccacgccgccagcaaccaggg-3′ 178(forward) hHB12bVL-65′-cttccgctgccgctgaatctgctgggcacgccgctgccctggttgctggcg-3′ 179 (reverse)hHB12bVL-7 5′-ttcagcggcagcggaagcggcaccgacttcaccctgaccatcaacagcctgg-3′180 (forward) hHB12bVL-85′-ctctgctggcagtagtaggttgctgcgtcctcggcctccaggctgttgatggtc-3′ 181(reverse) hHB12bVL-95′-aacctactactgccagcagagcaaggaggtgcccttcaccttcggcggcggc-3′ 182 (forward)DraIII + hHB12bVL-5′-gacactcggtgcagccacagtcttgatctccaccttggtgccgccgccgaag-3′ 183 10(reverse) hHB12b VH Hpal + hHB12bVH-15′-gttaacgaggtgcagctggtggagagcggcggcggcctggtgca-3′ 184 (forward)hHB12bVH-2 5′-cgctggcggcgcagctcagtctcaggctgccgccgggctgcaccaggccgccgc-185 (reverse) 3′ hHB12bVH-35′-gctgcgccgccagcggcttcaccttcagcagcagctggatgaactgggtgagac- 186 (forward)3′ hHB12bVH-45′-gattctgcccacccactccaggcccttgccgggggcctgtctcacccagttcatcc-3′ 187(reverse) hHB12bVH-55′-gagtgggtgggcagaatctaccccggcgacggcgacaccaactacaacggcaa 188 (forward)gttc-3′ hHB12bVH-65′-tcttgctgtcgtctctgctgatggtgaatctgcccttgaacttgccgttgtagttg-3′ 189(reverse) hHB12bVH-75′-ttcagcggcagcggaagcggcaccgacttcaccctgaccatcaacagcctgg-3′ 190 (forward)hHB12bVH-8 5′-atgaagccgcttctggcgcagtagtacacggcggtgtcctcggtcttcaggctgtt-191 (reverse) 3′ hHB12bVH-95′-cgccagaagcggcttcatcaccaccgtgctggacttcgactactggggccagggc- 192(forward) 3′ Apal + hHB12bVH-5′-gggccctttggtggaggcgctgctcacggtcaccagggtgccctggccccagtag- 193 10 3′(reverse)

TABLE 27 Primers for the cloning of F2F (Anti-CD20) VL and VH SEQ IDName of Primer Sequence NO F2F VL Nael-X-aCD20VL-15′-gccggccatggaagccccagctcagcttctcttcctcctgctactctggc-3′ 194 (forward)aCD20VL-2 5′-ctggagactgtgtcaacacaatttctccggtggtatctgggagccagagtagcaggagg195 (reverse) aag-3′ aCD20VL-35′-aattgtgttgacacagtctccagccaccctgtctttgtctccaggggaaagagccaccc- 196(forward) 3′ aCD20VL-45′-caggctaagtagctgctaacactctgactggccctgcaggagagggtggctctttcccc- 197(reverse) 3′ aCD20VL-55′-tgttagcagctacttagcctggtaccaacagaaacctggccaggctcccaggctcctc- 198(forward) 3′ aCD20VL-65′-ctggctgggatgccagtggccctgttggatgcatcatagatgaggagcctgggagcc-3′ 199(reverse) aCD20VL-75′-actggcatcccagccaggttcagtggcagtgggtctgggacagacttcactctcaccat- 200(forward) 3′ aCD20VL-85′-ctgacagtaataaactgcaaaatcttcaggctctaggctgctgatggtgagagtgaagt 201(reverse) ctgtcc-3′ aCD20VL-95′-gaagattttgcagtttattactgtcagcagcgtagcaactggccgatcaccttcggccaa 202(forward) gg-3′ DraIII − aCD20VL-5′-gacactcggtgcagccacagttttaatctccagtcgtgtcccttggccgaaggtgatc-3′ 203 10(reverse) F2F VH Hpal + aCD20VH-15′-gttaacatggagttgggactgagctggattttccttttggctatttta-3′ 204 (forward)aCD20VH-2 5′-ctccaccagctgcacttcacactggacaccttttaaaatagccaaaaggaaaatccag205 (reverse) c-3′ aCD20VhH-35′-gaagtgcagctggtggagtctgggggaggcttggtacagcctggcaggtccctg-3′ 206(forward) aCD20VH-45′-cataatcattaaaggtgaatccagaggctgcacaggagagtctcagggacctgccag 207(reverse) g-3′ aCD20VH-55′-gcctctggattcacctttaatgattatgccatgcactgggtccggcaagctccagggaag- 208(forward) 3′ aCD20VH-65′-ggaaccactattccaactaatagttgagacccactccaggcccttccctggagcttgcc- 209(reverse) 3′ aCD20VH-75′-tcaactattagttggaatagtggttccataggctatgcggactatgtgaagggccgattc- 210(forward) 3′ aCD20VH-85′-gatacagggacttcttggcgttgtctctggagatggtgaatcggcccttcacagag-3′ 211(reverse) aCD20VH-95′-cgccaagaagtccctgtatctgcaaatgaacagtctgagagctgaggacacggcc-3′ 212(forward) aCD20VH-105′-gtagtagttgccgtactgtatatcttttgcacagtaatacaaggccgtgtcctcagc-3′ 213(reverse) aCD20VH-115′-agatatacagtacggcaactactactacggtatggacgtaggggccaagggaccac- 214(forward) 3′ Apal − aCD20VH-125′-gggccattggtggaggctgaggagacggtgaccgtggtcccttggccc-3′ 215 (reverse)

Production of Recombinant PEG2×TAG72, PEG2×EGFR, PEG2-HER2, PEG×TAG72,PEG×EGFR and PEG×HERBsAbs

CHO-K1/PEG2×TAG72 and CHO-K1/PEG2×DNS cells that stably secretePEG2×TAG72 and PEG2×DNS BsAbs were generated by retroviral transductionof CHO-K1 Chinese hamster ovary cells. PEG2×TAG72, PEG2×EGFR, PEG2-HER2,PEG×TAG72, PEG×EGFR and PEG×HER BsAbs were produced by transienttransfection of 293FT cells with corresponding plasmids.293FT/h6.3Fab×CD19 and 293FT/h6.3Fab×EGFR cells that stably secretedh6.3Fab×CD19 and h6.3Fab×EGFR BsAbs were generated by lentiviraltransduction. Recombinant lentiviral particles were packaged byco-transfection of pAS3w. Ppuro-pAS3w. Ppuro-h6.3Fab×CD19 andpAS3w.Ppuro-h6.3Fab×EGFR (7.5 μg) with pCMVAR8.91 (6.75 μg) and pMD.G(0.75 μg) using TransIT-LT1 transfection reagent (Mirus Bio, Madison,Wis.) (45 μL) in 293FT cells grown in a 10 cm culture dish (90%confluency). After 48 hr, lentiviral particles were harvested andconcentrated by ultracentrifugation (Beckman SW 41 Ti UltracentrifugeSwing Bucket Rotor, 50,000 g, 1.5 hr, 4° C.). Lentiviral particles weresuspended in culture medium containing 5 μg/mL polybrene and filteredthrough a 0.45 μm filter. 293FT cells were seeded in 6-well plates(1×10⁵ cells/well) one day before viral infection. Lentivirus containingmedium was added to cells and then centrifuged for 1.5 hr (500 g, 32°C.). The cells were selected in puromycin (5 μg/mL) to generate stablecell lines. These anti-PEG BsAbs were purified by affinitychromatography on a TALON column. Briefly, the medium was harvested fromCELLine adhere 1000 bioreactors (INTEGRA Biosciences AG, Switzerland)every 7-10 days. Poly-histidine-tagged BsAbs were purified on aCo²⁺-TALON column (GE Healthcare Life Sciences, Piscataway, N.J.). Thecolumns were washed by 5-fold bed volumes of binding buffer (0.3 MNaCl/20 mM phosphate/HCl, pH 7.4) and followed by 10-fold bed volumes ofwashing buffer (0.3 M NaCl/20 mM phosphate/5 mM imidazole/HCl, pH 7.4).These poylhistidine-tagged BsAbs were eluted by elution buffer (0.3 MNaCl/20 mM phosphate/150 mM imidazole/HCl, pH 7.4). The eluted proteinswere desalted on Sephadex G-25, equilibrated with PBS and concentratedby ultrafiltration. Protein concentrations were determined by thebicinchoninic acid protein assay (Pierce, Rockford, Ill., U.S.A.).

Production of PEG×EGFR, PEG×HER2 and PEG×DNS BsAbs

To produce desired BsAbs, the BALB 3T3 producer cells were transfectedwith plasmids of this invention as described above, and weresubsequently sorted by FACS on a MoFlo™ XDP (Beckman coulter, Inc.,Brea, Calif.) at 4° C. and then incubated into CELLine (INTEGRABiosciences AG, Zizers, Switzerland) with 1% CCS DMEM. After collectingthe culture medium, BsAbs were purified by mPEG affinity chromatography,which was made by coupling 36 mg ofo-(2-aminoethyl)-o′-methylpolyethylene glycol 750 (Fluka-Sigma-Aldrich,St. Louis, Mo.) on 1 g of CNBr-activated Sepharose™ 4B (GE Healthcare,Little Chalfont, UK). This procedure was performed by following theinstruction manual of CNBr-activated Sepharose™ 4B (GE Healthcare).

Purification of Knob in Hole BsAbs

293FT cells stably expressing BsAbs were cultured in Cell Line adhere1000 (Integra Biosciences AG, Zizers, Switzerland) in DMEM with 10% lowbovine IgG medium (serum was pre-absorbed with protein A resin) at astarting cell number of 5×10⁷. Culture supernatant was harvested everyweek. The pooled supernatant was centrifuged at 800 g for 10 min at 4°C. to remove cells and subsequently centrifuged at 15000 rpm for 25 minat 4° C. to remove cell debris. Later on, the supernatant was passedthrough a 0.45 μM filter and G25 column in phosphate saline buffer(PBS), and finally the bsAb was affinity purified using protein Asepharose. After protein A purification, the purified products werefurther purified by affinity chromatography by CNBr-activated Sepharose™4B (Sigma-Aldrich Chemical Co, St. Louis, Mo., USA) conjugated with 35mg of methyl-PEG₁₀₀₀-NH2 per gram of CNBr activated Sepharose™ 4B.Subsequently, the purified bsAb were further purified by affinitychromatography using Pierce anti-HA agarose (Thermo Scientific, MA,USA). Purified bsAb fractions were dialyzed against 1000 volumes of PBSthree times and concentrated using Amicon Ultra (30 kD cutoff)(Millipore).

Analysis of the Purified BsAbs

Five microgram of BsAbs (such as PEG2×TAG72, PEG2×DNS, mPEG×EGFR,mPEG×HER2, mPEG×DNS, 15-2b/BU12, h6.3/BU12, h6.3Fab×EGFR, andh6.3Fab×CD19 BsAbs) were electrophoresed in 10% SDS-PAGE gels underreducing or non-reducing conditions and then stained by Coomassie Blue.

ELISA

The anti-PEG binding specificity of BsAbs was measured by adding gradedconcentrations of PEG2×TAG72, PEG2×DNS, hCC49 scFv, h6.3Fab×EGFR orh6.3Fab×CD19 in 50 μL 2% skim milk to the mucin, BSA-PEG5000,NH₂-PEG_(3k)-NH₂ or BSA coated plates at RT for 1 h. The plates werewashed with PBS-T (PBS containing 0.05% Tween-20) three times. Rabbitanti-6×His (2 μg/mL) supplemented with HRP-conjugated goat anti-rabbit(2 μg/mL) or HRP-conjugated goat Ig anti human IgG Fab (2 μg/mL)(Jackson ImmunoResearch Laboratories, West Grove, Pa.) in 50 μL dilutionbuffer were added for 1 h at room temperature. The plates were washedwith PBS-T (PBS containing 0.05% Tween-20) three times and with PBS twotimes. Bound peroxidase activity was measured by adding 150 μL/well ABTSsubstrate solution (BioLegend, San Diego, Calif.) for 30 min at roomtemperature. The absorbance (405 nm) of wells was measured in amicroplate reader (Molecular Device, Menlo Park, Calif.).

Flow Cytometer Analysis

PEG2×TAG72 or control PEG2×DNS BsAbs (10 μg/mL) were incubated withA-375(TAG72−), MCF-7(TAG72+), Jurkat (TAG72+) or OVCAR-3(TAG72+) cellsat 4° C. for 30 min followed by FITC-labeled goat anti-humanimmunoglobulin second antibody (2 μg/mL) (Jackson ImmunoResearchLaboratories, West Grove, Pa.) or FITC-labeled 4arm-PEG (2 μg/mL).Tumor-specific targeting of PEGylated compounds was also examined bystaining A431 (EGFR^(high)), and Raji (CD19^(high)) cell lines with 10μg/mL of h6.3Fab×EGFR or h6.3Fab×CD19 BsAbs in PBS containing 0.05% BSA(staining buffer) at 4° C. for 30 min. The cells were washed with coldPBS for 3 times. PEG-Qdot655 (8 nM) (Invitrogen, Grand Island, N.Y.) orPEG-liposomal Texas-Red (100 nm size, 50 μM, lipid conc.) (FormuMaxScientific, Palo Alto, Calif.) in staining buffer was added to cells for30 min at 4° C. Raji cells (CD19+) or SKBR3 cells (HER2+) were incubatedwith 10 μg/ml h15-2b-knob/BU12-hole, h15-2b-knob/anti-Her2-hole,h6-3-knob/BU12-hole or h6-3-knob/anti-Her2-hole BsAbs, washed andincubated with 0.25 μg/ml FITC-labeled goat anti-human IgG or 10 nMmethoxy-PEG Qdot 655 at 4° C. for 30 min. After washing with cold PBS,the surface fluorescence of 10⁴ viable cells was measured by FACScaliberflow cytometer (Becton Dickinson, Mountain View, Calif., USA) thenanalyzed with Flowjo (Tree Star Inc., San Carlos, Calif., USA).

Confocal Microscopy of BsAb-Targeted Nano-Particles

The coverslips (30 mm) in POC chambers were coated with 10 μg/mLpoly-L-lysine in PBS for 30 min at room temperature. The coverslips werewashed twice with PBS and then 5×10⁴ cells/chamber of A431 (EGFR⁺) tumorcells were seeded on the coverslips. A431 cells were incubated with 10μg/mL of h6.3Fab×EGFR or h6.3Fab×CD19 BsAbs at 37° C. for 30 mincontaining 1 μg/mL of Hoechst 33342 and 100 nM of LysoTracker® RedDND-99 (Invitrogen Life Technologies Corporation, NY, USA). The cellswere washed with culture medium for 2 times. Cell imaging was recordedwith an Axiovert 200M Confocal Microscope (Carl Ziess Inc., Thornwood,N.Y.) after adding 16 nM of PEG-Qdot655 solution (Invitrogen LifeTechnologies Corporation, NY, USA).

Cytotoxicity Assay

A431 (EGFR^(high)) and Raji (CD19^(high)) cells (5000 cells/well) wereseeded in 96-well plates overnight. Fifteen microgram per mL ofh6.3Fab×EGFR or h6.3Fab×CD19 BsAbs were added to the cells for 30 min at37° C. and followed by graded concentrations of free doxorubicin orPEGylated liposomal doxorubicin (Doxisome®, Taiwan Liposome CompanyLtd., Taipei, Taiwan) was added to the cells in triplicate at 37° C. for4 h. The cells were subsequently washed once and incubated for anadditional 48 h in fresh culture medium and then pulsed for 16 h with³H-thymidine (1 μCi/well). Results are expressed as percent inhibitionof ³H-thymidine incorporation into cellular DNA in comparison tountreated cells.

In Vivo Optical Imaging of PEG-NIR797 Probes

BALB/c nude mice bearing Ramos (CD19+) and A431 (EGFR+) tumor (˜250 mm³)in their hind leg regions were intravenously injected with h6.3Fab×EGFR(50 μg) and PEG-NIR791 (50 μg). Pentobarbital anesthetized mice weresequentially imaged with an IVIS spectrum optical imaging system(excitation, 745 nm; emission, 840 nm; Perkin-Elmer, Inc., MA, USA) at45 min, 24 and 48 hr after injection.

Detecting the Expressed Level of Tumor Markers on Colon and BreastCancer Cells

EGFR expression was measured by staining SW480 or SW620 cells with 1mg/ml Erbitux followed by 1 mg/ml FITC conjugated goat anti-human IgG Fc(Jackson Immuno-Research Laboratories, Westgrove, Pa.) at 4° C. The sameprocedure were used to measure HER2 expression of SK-BR-3 or MDA-MB-468cells, which were stained by 1 mg/ml Herceptin followed by 1 mg/ml FITCconjugated goat anti-human IgG Fc. After extensive washing with ice coldPBS, the surface immunofluorescence of viable cells was measured with aFACScan flow cytometer (BD Biosciences, San Diego, Calif.) andfluorescence intensities were analyzed with Cellquest pro software (BDBiosciences).

Bi-Functional Assay of PEG×EGFR and PEG×HER2

Ninety-six well plates were coated with 2 μg/well of poly-L-lysine (40μg/ml) in PBS for 5 min at room temperature, washed twice with PBS andthen coated with 2×10⁵ cells/well of SW480 (EGFR⁺) or SK-BR-3 (HER2⁺)tumor cells. PEG×EGFR, PEG×HER2 and PEG×DNS (10 μg/ml) were added to thewells at room temperature for 1 h. The wells were then washed threetimes with DMEM and 200 ng/ml of Lipo/DOX, 66.7 ng/ml of Lipo/IR780, 100ng/ml of SN38/PM, 600 ng/ml of FeOdots, 0.5 nM of AuNP and 0.5 nM ofQdot_(565 nm) were added to the wells for 20 mins. After extensivewashing with DMEM, the concentrations of PEG-NPs were determined byadding 5 μg/ml of anti-PEG backbone Ab (6-3 Ab from 6-3 hybridoma) for 1hr, and then DMEM washing three times. In order to amplifying thesignals, 0.4 μg/ml of goat anti-mouse IgG Fc-HRP (Jackson ImmunoResearchLaboratories, Inc., PA, USA) was added to the wells. Washing wellsfourth times with DMEM, followed by ABTS substrate before absorbancevalues at 405 nm were measured in a microplate reader (Molecular Device,Menlo Park, Calif., USA).

Non-Covalent Modification of PEG-NPs with PEG×EGFR and PEG×HER2

BsAbs were added to the PEG-NPs in BSA/PBS buffer (0.05% BSA in 1×PBSbuffer) at 4° C. for 1 h at protein/PEG-NP ratios of 380-570 μgBsAb/μmol doxorubicin (for Lipo/DOX), 550 μg BsAbs/μmol FeOdot and 140ng BsAbs/pmol Qdots. After PEG×EGFR or PEG×HER2 modification, PEG-NPsbecame αEGFR-NPs or αHER2-NPs.

Confirm the Conversion of Non-Targeted NPs to Targeted NPs

Ninety-six well plates were coated with 2 μg/well of poly-L-lysine (40μg/ml) in PBS for 5 min at room temperature, washed twice with PBS andthen coated with 2×10⁵ cells/well of SW480 (EGFR+), SW620 (EGFR⁻),SK-BR-3 (HER2⁺) or MDA-MB-468 (HER2⁻) tumor cells. SW480 (EGFR⁺) andSW620 (EGFR⁻) cells were incubated with 4 μg/ml of αEGFR-Lipo/DOX, 1μg/ml of αEGFR-Lipo/IR780 and 4 μg/ml of FeOdots for 20 mins. Afterextensive washing with DMEM, the concentrations of PEGylated NPs weredetermined by adding 5 μg/ml of anti-PEG backbone Ab (6-3 Ab) for 1 hr,and then DMEM washing three times. In order to amplifying the signals,0.4 μg/ml of goat anti-mouse IgG Fc-HRP (Jackson ImmunoResearchLaboratories, Inc., PA, USA) was added to the wells. Washing wells withDMEM, followed by adding ABTS substrate before absorbance values at 405nm were measured in a microplate reader (Molecular Device, Menlo Park,Calif., USA). The same procedure was used to examine SK-BR-3 (HER2⁺) andMDA-MB-468 (HER2⁻) cells that were stained with 4 μg/ml ofαHER2-Lipo/DOX, 4 μg/ml of FeOdots and 2 nM of αEGFR-Qdot_(565 nm) for20 mins.

Confocal Microscopy of BsAb-Targeted NPs

Circular coverslips (18 mm) in 12 wells plate were coated with 20μg/well of poly-L-lysine (40 μg/ml) in PBS for 5 min at roomtemperature. The coverslips were washed twice with PBS and then 4×10⁴cells/well of SW480 (EGFR⁺), SW620 (EGFR⁻), SK-BR-3 (HER2⁺) orMDA-MB-468 (HER2⁻) tumor cells were coated on the coverslips. SW480(EGFR⁺) and SW620 cells (EGFR⁻) were incubated with 300 ng/ml ofαEGFR-Lipo/Rho and αDNS-Lipo/Rho at 37° C. for 1 h. The cells were fixedwith 2% paraformaldehyde in PBS for 30 min at 4° C. and were stainedwith DAPI for 45 min at 4° C. Then, the coverslips were washed 4 timeswith PBS, and then mounted with fluorescent mounting medium (Dako,Glostrup, Denmark) on glass microscope slide. The fluorescent signals ofαEGFR-Lipo/Rho and αDNS-Lipo/Rhowere recorded with an Olympus FluoView™FV1000 Confocal Microscope (Olympus Imaging America Inc., Center Valley,Pa.). The same procedure was used to image SK-BR-3 (HER2⁺) andMDA-MB-468 (HER2⁻) cells which were stained with 4 nM ofαHER2-Qdot_(565 nm) and αDNS-Qdot_(565 nm), respectively.

Targeting of BsAb-Targeted FeOdots by MR Imaging

MR imaging was performed with a clinical 3.0 T MR imager (Signa; GEHealthcare, Little Chalfont, UK). 1×10⁷ SW480 (EGFR⁺) or SW620 (EGFR⁻)cells were incubated with different concentrations of αEGFR-FeOdots orαDNS-FeOdots (7 μM, 14 μM and 28 μM) at 4° C. for 30 min. The cells werewashed with PBS 3 times and then the accumulation of BsAbs-FeOdots werescanned by T2-weighted fast spin-echo sequence (TR/TE=2500 ms/60 ms).The same protocol was used to examine localization of αHER2-FeOdots andαDNS-FeOdots at SK-BR-3 (HER2⁺) and MDA-MB-468 (HER2⁻) cells.

In Vitro Cytotoxicity of BsAb-Targeted Lipo/DOX

SW480 (EGFR⁺) and SW620 (EGFR⁻) cells (3×10³/well) were seeded in96-wells plates. 2 μg/ml or 4 μg/ml of αEGFR-Lipo/DOX, αDNS-Lipo/DOX,and Lipo/DOX were added to each well and incubated at 37° C. for 1 h.The medium was replenished and the cells were incubated for 72 h beforecell viability was measured with the ATPlite™ Luminescence Assay System(Perkin-Elmer, Inc., Waltham, Mass.). Cell viability for SK-BR-3 (HER2⁺)or MDA-MB-468 (HER2⁻) cells incubated with αHER2-Lipo/DOX,αDNS-Lipo/DOX, or Lipo/DOX at 37° C. for 3 h were measured in accordancewith the same procedures. Results were expressed as percent inhibitionof luminescence as compared with untreated cells by the followingformula: % inhibition=100×(treated luminescence/untreated luminescence).The standard deviation for each data point was averaged over threesamples (n=3).

In Vivo Optical Imaging of BsAb-Lipo/IR780 and Lipo/IR780

BALB/c nude mice bearing SW480 (EGFR⁺) and SW620 (EGFR⁻) tumor(approximately 100 mm³) in their hind leg regions, were intravenouslyinjected with αEGFR-Lipo/IR780, αDNS-Lipo/IR780, and Lipo/IR780 (100 μgper mouse), respectively. Pentobarbital anesthetized mice weresequentially imaged with an IVIS spectrum optical imaging system(excitation, 745 nm; emission, 840 nm; Perkin-Elmer, Inc., Waltham,Mass.) at 24, 48 and 72 h after injection.

Treatment of EGFR⁺ and EGFR⁻ Tumors with BsAb-Lipo/DOX and Lipo/DOX

BALB/c nude mice (n=6) were inoculated s.c. with 4×10⁶ SW480 (EGFR⁺)cells and 1×10⁶ SW620 (EGFR⁻) cells in their hind leg regions. Aftertumor sizes reached to about 20 mm³, Lipo/DOX, αDNS-Lipo/DOX andαEGFR-Lipo/DOX were i.v. administered at 5 mg DOX/kg once weekly for 3weeks, for a total dose of 15 mg DOX/kg. Other treatment groups includedsaline. Tumor measurements were performed 3 times a week using acaliper, and tumor sizes were calculated using the equation:(length×width×high)/2. Mice were weighted once a week to examine thetoxicity.

Statistic Analysis.

Statistical significance of differences between mean values wasestimated with JMP 9.0 software (SAS Institute, Inc., Cary, N.C.) usingthe nonparametric Mann-Whitney test. P-values in the cytotoxicity assayand in vivo toxicity<0.05 and the P-values in the in vivo treatment<0.01were considered to be statistically significant.

Example 1 Production and Characterization of Dimeric HumanizedBi-Specific Antibodies (BsAbs)

1.1 Production of Murine Anti-mPEG or Anti-PEG Abs

In order to produce humanized BsAbs, three hybridoma cells, E11, 15-2band 6-3, were identified, and their respective monoclonal Abs werecollected by affinity chromatography. The binding specificity of thecollected antibodies toward immobilized PEG was then determined. Anexemplary binding specificity between monoclonal antibody produced byhybridoma 15-2b and PEG is illustrated in FIG. 4.

As evident from FIG. 4, monoclonal antibody produced by hybridoma 15-2bbound with CH₃-PEG₇₅₀-NH2, instead of NH₂-PEG₃₀₀₀-NH2; which indicatesthat such monoclonal antibody specifically recognized the terminalmethoxy group of the CH₃-PEG molecules or the terminal hydroxyl group ofPEG molecules (FIG. 4), and is thus termed anti-mPEG Ab; whereas theantibody produced by hybridoma 6-3 or E11 specifically recognized thebackbone portion and not the terminal methoxy or hydroxyl group or thePEG molecules, and is thus termed anti-PEG Ab.

DNA encoding the anti-mPEG or anti-PEG Abs was then isolated andsequenced using conventional procedures (i.e., by using oligonucleotideprobes that are capable of binding specifically to genes encoding theheavy and light chains of the monoclonal Abs).

1.2 Production of Dimeric Humanized Anti-PEG (hE11) Anti-TAG72 BsAb

To produce humanized Abs with bispecificity, the DNA sequence of murineanti-mPEG mAb of example 1.1 was humanized and fused with a humanizedsingle-chain antibody fragment gene against tumor-associatedglycoprotein 72 (TAG-72) antigen (hcc49 scFv) or a dansyl (DNS) haptenin accordance with procedures described in the Materials and Methodssection.

FIG. 5A is a schematic illustration of the DNA constructs of thehumanized bi-specific Abs prepared in this example. In general, eachconstruct encoded in sequence, HA epitope tag (HA), the hE11 anti-PEGlight chain, a F2A bicistronic element, the hE11 anti-PEG heavy chain, ahinge-CH₂—CH₃ domain, a linker peptide (L), an anti-tumor scFv sequence(e.g., hcc49 scFv for PEG2×TAG72 plasmid, and anti-dansyl scFv for thecontrol PEG2×DNS plasmid), and a histidine tag. FIG. 5B is a schematicillustration of the dimeric humanized anti-PEG BsAb of this example.Accordingly, BsAbs including PEG2×TAG72 and PEG2×DNS were produced.SDS-PAGE analysis indicated that BsAbs were composed by aVH-CH1-H-CH2-CH3-scFv fragment (72 kDa) and light chain (35 kDa) underreducing condition (FIG. 5C, right panel); by contrast, a 230 kDadisulfide-linked BsAbs was observed under non-reducing condition (FIG.5C, left panel). The result was further confirmed by a western blotanalysis, in which the HA epitope tag on the N-terminus of the hE11anti-PEG light chain and the His epitope tag present on the C-terminusof the scFv attached to the hE11 anti-PEG heavy chain were detected,demonstrating that the bispecific antibody was present in the expectedconformation (FIG. 5D).

1.3 Characterizing the Function of BsAbs of Example 1.2

Bi-functional activity of the humanized hE11 BsAbs of example 1.2 wasexamined in this example.

Binding of the BsAbs was detected by ELISA. Microtiter plates were firstcoated with antigens and then PEG2×TAG72, PEG2×DNS BsAbs or hCC49(anti-TAG72) single chain antibody was added. After the plates wereextensively washed to remove unbound antibodies, the remaining boundantibodies in each well were detected with HRP-conjugated secondaryantibody. The PEG2×TAG72 BsAb was able to bind to both mucin (TAG-72tumor antigen) (FIG. 6A) as well as BSA-PEG (FIG. 6B) but not to BSA(FIG. 6C), demonstrating that PEG2×TAG72 displayed dual antigenspecificity to both PEG and mucin. By contrast, the control PEG2×DNSBsAb bound to BSA-PEG but not to mucin. Likewise, the hcc49 scFv boundto mucin but not to BSA-PEG. In sum, PEG2×TAG72 anti-PEG (hE11) BsAb ofexample 1.2 can bind both PEG and tumor antigens.

To determine if the hE11 BsAbs of example 1.2 could bind target cells,MCF-7 breast cancer, Jurkat T cells and OVCAR-3 ovarian cancer cells,which express the TAG-72 antigen recognized by the hCC49 antibody, wereincubated with PEG2×TAG72 and PEG2×DNS BsAbs. A-375 malignant melanomacells, which do not express the TAG-72 antigen, were used as a negativecontrol cell line. After washing unbound BsAbs from the cells, the BsAbsthat remained bound to cells were detected with FITC-conjugatedanti-human immunoglobulin antibody. Detection of surfaceimmunofluorescence in a flow cytometer demonstrated that TAG-72 positivecells bound PEG2×TAG72 BsAb but not the control PEG2×DNS BsAb (FIG. 7,left panels). To test if PEG2×TAG72 could simultaneously bind to cancercells and PEGylated molecules, the cells were first incubated withBsAbs, washed and then incubated with FITC-labeled PEG molecules. TAG-72positive cells incubated with PEG2×TAG72 BsAb but not the controlPEG2×DNS BsAb could bind PEG-FITC, demonstrating that PEG2×TAG72 actedas a true BsAb which could simultaneously bind tumor antigens and PEGmolecules (FIG. 7, right panels).

1.4 Production and Characterization of Dimeric Humanized Anti-PEG (hE11)Anti-EGFR or Anti-HER BsAbs

To assess whether other cellular targets could be targeted by anti-PEGBsAbs, single-chain antibody fragment genes against epidermal growthfactor receptor (EGFR) and the HER2 antigen was fused to the C-terminusof the heavy chain C_(H3) region gene of the humanized E11 antibody togenerate PEG2×EGFR and PEG2×HER2, respectively in accordance withsimilar procedures of example 1.2.

Assessment of the ability of these BsAbs to bind cancer cells indicatedthat PEG2×TAG72 bound with Jurkat T cells (Tag-72 positive) but notMDA-MB-468 cells or BT-474 cells. By contrast, PEG2×EGFR BsAb bound toMDA-MB-468 cells (EGFR positive) but not the other two cells, whereasPEG2×HER2 BsAbs bound specifically with BT-474 cells (HER2 positive)(FIG. 8A). Thus, these BsAbs bound to respective target cells in anantigen-dependent manner.

The ability of the bispecific antibodies to simultaneously bind cancercells and PEGylated compounds was further investigated by firstincubating cells with BsAbs, washing unbound antibody from the cells andthen adding PEG-liposomal Texas Red or PEG-Qdot655 (PEGylated quantumdots). Each BsAb selectively accumulated PEGylated liposomes (FIG. 8B)or PEGylated nanoparticles (FIG. 8C) at cells that expressed thecorresponding target antigen on their surface.

In sum, the anti-PEG BsAbs of this example can simultaneously bind totarget antigens and PEGylated substances to selectively accumulatePEGylated compounds and nanoparticles on their respective target cells.

Example 2 Production and Characterization of Monovalent Humanized BsAbs

2.1 Production and Characterization of Monovalent Anti-PEG (E11) BsAbs

Monovalent anti-PEG BsAbs were generated by fusing the Fab fragment of ahumanized antibody derived from the anti-PEG antibody E11 to singlechain antibodies with specificity for tumor-associated antigens.

Specifically, the hE11 Fab fragment was fused a single-chain antibodyfragment (scFv) derived from anti-TAG72, anti-EGFR (epidermal growthfactor receptor) or anti-HER2/Neu antibodies (FIG. 9). CHO cells thatstably expressed the monovalent BsAbs were generated and culture mediumfrom each expression cell line was collected.

The binding specificity of monovalent BsAbs with their target proteinswas measured by collecting the culture medium of BsAbs producing cells,adding the collected medium to cells that expressed the target protein,then determining the binding by ELSA. After washing the cells, the boundBsAbs were detected by FITC-labeled goat anti-human immunoglobulinsecond antibody. It was found that PEG×TAG72 bound to Jurkat T cells(Tag-72 positive), but not MDA-MB-468 cells or BT-474 cells. Bycontrast, PEG×EGFR BsAb bound to MDA-MB-468 cells (EGFR positive) butnot the other two cells; whereas PEG×HER2 BsAb was found to bind withBT-474 cells (HER2 positive) specifically (FIG. 10). Thus, monovalentanti-PEG (hE11) BsAbs bound to target cells in an antigen-dependent andselective manner.

The ability of the monovalent BsAb to simultaneously bind with cancercells and PEGylated compounds was examined by incubating target cellswith BsAbs and PEGylated substances. After washing out the unboundantibody from the cells, PEG-liposomal Texas Red or PEG-Qdot655(PEGylated quantum dots) were then added. Each BsAbs selectivelyaccumulated PEGylated liposomes (FIG. 11) or PEGylated nanoparticles(FIG. 12) at cells that expressed the corresponding target antigen ontheir surface. Thus, monovalent anti-PEG (hE11) BsAbs can simultaneouslybind to target antigens and PEGylated substances to selectivelyaccumulate PEGylated compounds and nanoparticles on the surface of thetarget cells.

2.2 Production and Characterization of Monovalent Anti-PEG (h6.3) BsAbs

The humanized anti-PEG (h6.3) Fab was constructed as a single openreading frame by fusing V_(L)-Cκ and V_(H)-CH1 with a F2A (furin-2A)peptide linker, allowing the expression of light chain and heavy chainseparately in accordance with procedures described in the “Materials andMethods” section. The single chain disulfide-stabilized variablefragments (dsFv) were linked to the C-termius of the CH1 domain in the6.3Fab via a peptide linker to generate h6.3-11F8 (h6-3Fab×EGFR) andh6.3-hBU12 (h6.3Fab×CD19) BsAbs (FIG. 13A). These two BsAbs were theninserted into a lentiviral expression vector to generate stable 293FTproducer cell lines. BsAbs (including h6-3Fab×EGFR and h6.3Fab×CD19)that were purified from the culture medium displayed the expectedmolecular sizes on a 10% SDS-PAGE (FIG. 13B).

Further, both h6-3Fab×EGFR and h6.3Fab×CD19 BsAbs bound to theNH₂-PEG_(10,000)-NH2, but not to the control BSA protein, indicatingtheir binding specificity toward PEG molecule (FIGS. 14A and 14B). As totheir binding specificity toward the target antigen, flow cytometeranalysis revealed that h6.3Fab×EGFR, but not h6.3Fab×CD19, was capableof directing the PEGylated substance (including PEG-liposome Texas Redand PEG-Qdot655) to A431 cells (EGFR+); whereas h6.3Fab×CD19, but noth6.3Fab×EGFR, was capable of directing PEGylated substance to Raji cells(CD19+) (FIG. 14C). The PEG-binding kinetics of h6-3Fab×EGFR andh6.3Fab×CD19 BsAbs were verified by Microscale Thermophoresis (MST)(FIGS. 14D and 14E).

To verify whether BsAb-targeted substance could be internalized byantigen-positive cancer cells, live cell imaging was performed bystaining cells with lysosome tracker and BsAbs, followed by the additionand incubation of PEG-Qdot655. It was found that h6.3Fab×EGFR treatedA431 cells displayed red fluorescence within endocytic vesicles, whereash6.3Fab×CD19 treated A431 cells failed to produce PEG-Qdot655 signals(FIG. 15). This observation indicates that h6.3Fab×EGFR mediated EGFRendocytosis allows the uptake of PEG-substance into A431 cells.

Next, the ability of whether h6.3Fab×CD19 and h6.3Fab×EGFR BsAbs couldincrease the cytotoxicity of the drug-loaded nanoparticles (NPs) toantigen-positive cancer cells was investigated. Raji (CD19⁺) and A431(EGFR⁺) cells were incubated with h6.3Fab×CD19 and h6.3Fab×EGFR,followed by the addition of graded concentrations of Doxisome (i.e.,PEGylated liposomal doxorubicin). When compared with Doxisome alone,both h6.3Fab×CD19 and h6.3Fab×EGFR enhanced cytotoxicity of Doxisome toRaji, MDA-MB-468 and A431 cells, respectively (FIGS. 16A to 16C). Theresults indicate that anti-PEG (h6.3) BsAbs may confer tumor selectivityand increase the cytotoxicity of a PEGylated NPs (e.g., doxisome) toantigen-positive cancer cells.

To determine tumor targeting of anti-PEG (h6.3) BsAbs-NPs in vivo,BALB/c nude mice bearing Ramos (CD19, left side) and SW480 (EGFR, rightside) tumors in their hind leg regions were intravenously injected withh6.3Fab×EGFR and PEG-NIR797 probes. The mice were then imaged at 45 min,24 and 48 hours after injection using an IVIS spectrum optical imagingsystem. Enhanced signals of PEG-NIR797 were observed in A431 tumors butnot in Ramos tumors (FIG. 17), demonstrating that h6.3Fab×EGFR BsAbspreferentially deliver PEG probes to EGFR on antigen-positive tumors invivo.

2.3 Production and Characterization of Monovalent Anti-mPEG (h15.2b)BsAbs

In this example, the DNA sequence of murine anti-mPEG mAb of example 1.1was humanized and combined with another nucleic acid encoding a singlechain variable fragment (scFv) of EGFR or HER2 in accordance withprocedures described in the Materials and Methods section.

FIG. 18A is a schematic illustration of the DNA constructs of thehumanized bi-specific Abs prepared in this example, and 3 BsAbsincluding PEG×EGFR, PEG×HER2 and PEG×DNS were produced. In general, eachconstruct encoded in sequence, a signal peptide (SP), HA epitope tag(HA), the anti-mPEG light chain, a F2A bicistronic element, theanti-mPEG heavy chain Fd fragment, a myc epitope tag, a 15 amino acidflexible linker peptide (L) and scFv against an anti-tumor markersequence, such as anti-EGFR scFv for PEG×EGFR plasmid, and anti-HER2scFv for PEG×HER2 plasmid, and anti-dansyl scFv for the control PEG×DNSplasmid. Accordingly, 3 BsAbs including PEG×EGFR, PEG×HER2 and PEG×DNSwere produced. SDS-PAGE analysis indicated that BsAbs were composed by aFd-scFv fragment (56 kDa) and light chain (35 kDa) under reducingcondition; by contrast, a 91 kDa disulfide-linked BsAbs was observedunder non-reducing condition (FIG. 18B).

The thus produced humanized BsAbs were then subjected to bi-functionalactivity assay in antigen-positive or antigen-deficient cancer cells.Briefly, cells with over expressed EGFR (i.e., SW480, EGFR⁺) or HER2(i.e., SK-BR-3, HER2⁺) were first incubated with humanized BsAbs of thisexample, and the unbound BsAbs were washed out with a buffer solution,various PEG-NPs (i.e., Lipo/DOX, Lipo/IR780, SN38/PM, FeOdot, AuNP, andQdot_(565 nm)) were then added, and the respective binding activities ofthe BsAbs were detected by ELISA with an anti-mPEG antibody.

It is noted that PEG×EGFR, instead of the negative control PEG×DNS,mediated binding of all the tested PEG-NPs to EGFR⁺ SW480 cancer cells(FIG. 18C). Likewise, PEG×HER2, but not PEG×DNS, mediated the binding ofPEG-NPs to HER2⁺ SK-BR-3 cancer cells (FIG. 18D). In sum, both PEG×EGFRand PEG×HER2 display bi-functional binding activity, and are capable ofmediating the cross-linking of PEG-NPs to cells that express the EGFR orHER2 tumor markers.

To evaluate whether the BsAb of this example may confer cancer cellspecificity to the PEG-NP, the BsAbs of this example were added tovarious PEG-NPs (e.g., Lipo/DOX, Lipo/IR780 and FeOdot) to generatetargeted PEG-NPs. Binding specificity was then measured by ELISA.Results are depicted in FIGS. 19A and 19B. It is found that PEG-NPstargeting depends on the anti-EGFR portion of the BsAb, for the controlαDNS-NPs failed to bind to either SW480 (EGFR⁺) or SW620 (EGFR⁻) tumorcells (FIG. 19A) Likewise, incubating PEG-NPs with PEG×HER2, allowed theNPs to bind with SK-BR-3 (HER2⁺) tumor cells, but not MDA-MB-468 (HER2⁻)tumor cells (FIG. 19B). These results demonstrate that mixing PEG×EGFRor PEG×HER2 with PEG-NPs can endow the NPs with specificity to EGFR orHER2 on cancer cells.

The ability of the targeted PEG-NP in killing antigen-positive cancercells were further investigated, and results are provided in FIGS. 20Ato 20D. As depicted in FIG. 20A, αEGFR-Lipo/DOX exhibited highercytotoxicity to SW480 (EGFR⁺) cancer cells, as compared with that ofLipo/DOX or αDNS-Lipo/DOX (FIG. 20A). By contrast, αEGFR-Lipo/DOXdisplayed similar cytotoxicity as to that of Lipo/DOX or αDNS-Lipo/DOXto SW620 (EGFR⁻) tumor cells (FIG. 20B). Likewise, αHER2-Lipo/DOX wassignificantly more cytotoxic to SK-BR-3 (HER2⁺) cancer cells than thatcaused by Lipo/DOX or αDNS-Lipo/DOX (FIG. 20C). However, αHER2-Lipo/DOXdisplayed similar cytotoxicity to MDA-MB-468 (HER2⁻) cancer cells ascompared with that of Lipo/DOX or αDNS-Lipo/DOX (FIG. 20D). Accordingly,it is reasonable to conclude that anti-mPEG BsAbs may confer tumorselectivity and increase the cytotoxicity of a PEG-NP (Lipo/DOX) toantigen-positive cancer cells.

To investigate tumor targeting of BsAbs-NPs in vivo, BALB/c nude micebearing EGFR⁻ SW620 (left side) and EGFR SW480 (right side) tumors intheir hind leg regions were intravenously injected withαEGFR-Lipo/IR780, αDNS-Lipo/IR780 or Lipo/IR780. The mice were imaged at24, 48 and 72 hrs after injection with an IVIS spectrum optical imagingsystem. The fluorescent signal of αEGFR-Lipo/IR780 was enhanced in SW480(EGFR⁺) tumors as compared to SW620 (EGFR⁻) tumors from 24 to 72 hrsafter probe injection (FIG. 21, bottom row). The fluorescent intensityof αEGFR-Lipo/IR780 in SW480 (EGFR⁺) tumor were 2.037, 2.318 and2.328-fold greater at 24, 48 and 72 hrs than SW620 (EGFR⁻) tumor,respectively (Table 28). By contrast, Lipo/IR780 and αDNS-Lipo/IR780localized more strongly in SW620 tumors, presumably by the EPR effect.These data indicate that αEGFR-Lipo/IR780 possessed selectivity for EGFRcancer cells, thereby facilitating enhanced accumulation in EGFR⁺tumors.

TABLE 28 The region of interest (ROI) ratio of SW480 (EGFR⁺) to SW620(EGFR⁻) tumors was determined at the indicated times Time i.v. injectionROI ratio 24 h 48 h 72 h Lipo/IR780 EGFR ⁺ 0.93 0.93 0.92 EGFR⁻αDNS-Lipo/IR780 EGFR ⁺ 1.09 0.97 1.01 EGFR⁻ αEGFR-Lipo/IR780 EGFR ⁺ 2.042.32 2.33 EGFR⁻

To examine whether PEG×EGFR of this example may increase the therapeuticefficacy of Lipo/DOX to EGFR tumors in vivo, BALB/c nude mice bearingSW480 (EGFR⁺) and SW620 (EGFR⁻) tumor in their hind leg regions weretreated with Lipo/DOX αEGFR-Lipo/DOX, αDNS-Lipo/DOX or saline. It wasfound that αEGFR-Lipo/DOX suppressed the growth of SW480 (EGFR⁺) tumorssignificantly more than that treated by Lipo/DOX (P<0.01 on day 8 to 45)(FIG. 22A) without any apparent toxicity, as determined by mouse bodyweight (FIG. 22C). In the SW620 (EGFR⁻) tumor model, there were nosignificant differences between tumor sizes in mice treated withαEGFR-Lipo/DOX, αDNS-Lipo/DOX or Lipo/DOX (FIG. 22B). Accordingly, it isreasonable to conclude that PEG×EGFR of this example may indeed enhancethe anti-tumor efficacy of Lipo/DOX to EGFR tumors in vivo.

2.4 Production and Characterization of Monovalent Anti-mPEG (h15.2b)Anti-CD19 or Anti-CD20 BsAbs

In this example, the humanized single chain variable fragment (scFv) ofmurine anti-mPEG mAb was combined with another nucleic acid encoding themonomeric IgG of CD19 or CD20 in accordance with procedures described inthe Materials and Methods section.

FIG. 23A is a schematic illustration of the DNA constructs of thehumanized bi-specific Abs prepared in this example. In general, eachconstruct encoded in sequence, a signal peptide (SP), an anti-CD19 oranti-CD20 heavy chain sequence (VH-CH1), an anti-CD19 or anti-CD 20light chain sequence (VL-Cκ), an amino acid flexible linker peptide (L),and the anti-mPEG scFv. Accordingly, 2 anti-mPEG BsAbs respectivelydirected to CD19 and CD20 were produced. Binding results confirmed thatthe anti-mPEG BsAbs of the present example specifically bound to cellsthat positively expressed CD19 and CD20 (e.g., Raji cells) (FIG. 23B),as well as the terminal methoxy or hydroxyl group of PEG molecules (FIG.23C). Further, once the anti-mPEG BsAbs of the present example was mixedwith therapeutic nanoparticles (e.g., Lipo/DOX), they were able totarget deliver the therapeutic nanoparticles to CD19 or CD-20 positivecancer cells (FIG. 23D).

Example 3 Construction and Characterization of Dimeric Humanized Knob inHole BsAbs

3.1 Production of Knob in Hole Anti-PEG (h6.3 or h15.2b) Anti-HER2 orAnti-CD19 BsAbs

Recombinant DNA technology was utilized to create BsAbs derived from thecDNA coding regions of V_(H) and V_(L) of either an anti-HER2 antibody(C6) or an anti-CD19 antibodies (BU12), and the humanizedanti-methoxy-PEG monoclonal h15-2b or the humanized anti-PEG antibodyh6.3, with the employment of the “knobs-into-holes” strategy andimmunoglobulin domain crossover approach, for heterodimer formation andcorrect antibody heavy chain and light assembly.

For generating correctly assembled antibody, the light chain Cκ domainand heavy chain CH1 domain within the antigen binding fragment (Fab) ofeither BU12 or C6 antibody were exchanged, while the anti-PEG antibodieswere kept unmodified. In particular, Cκ of the tumor antigen antibodiesBU12 and C6 was replaced with the partial C_(H1) fragment and partialhinge of that antibody heavy chain, and the original C_(H1) fragmentsite within antibody heavy chain was replaced with the Cκ sequence ofthe antibody light chain. This allows the light chain to pair with itscognate heavy chain, instead of pairing with the heavy chain of theanti-PEG-knob antibody. Also, for heavy-chain heterodimer formation, aknob structure (T366W and S354C) was introduced into the h15-2b and h6.3CH3 region and a hole structure (T366S, L368A, Y407V and Y349C) wasintroduced into CH3 of C6 and BU12, respectively. The construction mapsof BsAbs constructed from the anti-mPEG (h15-2b)-knob antibody andBU12-hole or anti-HER2-hole antibodies are depicted in FIG. 24A; whereasthe DNA maps of BsAbs constructed from the anti-PEG antibody (h6.3)-knoband BU12-hole or anti-HER2-hole antibodies are illustrated in FIG. 24B.

The DNA constructs of BsAbs were then inserted into a lentiviralexpression vector to generate stable 293FT producer cell lines. BsAbs(including h15-2b knob+BU12-hole, h6.3+BU12-hole) that were purifiedfrom the culture medium displayed the expected molecular sizes on a 10%SDS-PAGE (FIG. 24C).

3.2 Characterization of Knob in Hole BsAbs of Example 3.1

In this example, the bi-specificity of the purified knob in hole BsAbsof example 3.1 was investigated. Briefly, Ramos cells (CD19⁺) and SKBR3cells (HER2⁺) were used to verify whether purified BsAbs can bind toboth PEG compounds and cancer cells that express the CD19 or Her2/neutumor antigens. Briefly, Ramos cells (CD19⁺), Raji cells (CD19⁺) orSKBR3 cells (HER2⁺) were incubated with 10 μg/ml h15-2b-knob/BU12-holeor h15-2b-knob/anti-Her2-hole BsAbs, washed and incubated with 0.25μg/ml FITC-labeled goat anti-human IgG or 10 nM methoxy-PEG Qdot 655 at4° C. for 30 min. The surface fluorescence of viable cells was measuredon a FACSCalibur. Results are illustrated in FIGS. 25 to 28.

It was found that h15-2b-knob/BU12-hole BsAbs bound to CD19-positiveRamos cells, but not to SKBR3 cells; whereas h15-2b-knob/anti-HER2-holeBsAbs bound to SKBR3 (Her2-positive) (FIG. 25). This indicates thath15-2b BsAbs retained the ability to specifically bind to cancer cellsin an antigen-dependent fashion. More importantly, h15-2b-knob/BU12-holecould stably retain PEGylated Qdots at Ramos and Raji cells; andh15-2b-knob/anti-HER2-hole could retain the Qdots at SKBR3 cell (FIG.26). Thus, these reagents acted as true bispecific molecules. Similarresults were observed for h6.3-knob/BU12-hole BsAbs, which could bind tocells expressing CD19 (Ramos and Raji) as measured by FACs (FIG. 27).h6.3-knob/BU12-hole also effectively bound PEG-modified Qdots to Rajicells (FIG. 28), demonstrating that this BsAb could simultaneously bindto CD19 on cancer cells and the PEG molecule of a PEGylatednanoparticle.

Example 4 Construction and Characterization of Recombinant IntactAnti-Cancer BsAbs

4.1 Production of Herceptin/h-α-PEG and Erbitux/h-αPEG Abs

To create reagents that may synergistically attack cancer cells, afunctional and humanized anti-PEG single-chain Ab (h-αPEG scFv) wasfused to the C-terminal of commercial available targeted antibodies(including Herceptin and Erbitux) to form bi-functionalHerceptin/h-αPEG, and Erbitux/h-αPEG Abs (FIG. 29). Accordingly, notonly have the original anticancer effects of the herceptin and/orErbitux antibodies been retained, but the newly produced BsAbs can alsoactively bind to PEGylated drugs at tumor sites, to produce synergisticanticancer effects (i.e., double-attack strategy).

4.2 Characterization of the Function of BsAbs of Example 4.1

In this example, the bi-functional activity of BsAbs of example 4.1 wasinvestigated. Briefly, SKBR-3 human breast adenocarcinoma cells, whichoverexpress the HER2/c-erb-2 gene product, were coated in 96-wellmicrotiter plates; then Herceptin/h-αPEG antibodies and controlHerceptin antibodies were added to the microtiter plates. After theunbound bi-functional antibodies were washed out, PEGylated liposomescontaining doxorubicin therein (herein Lipo-DOX) were added to thewells. Binding of the PEGylated compounds was determined by ELISA.

As expected, Herceptin/h-αPEG, but not control Herceptin antibodies,selectively bound Lipo-DOX to SKBR-3 cells (FIG. 30A). Similar resultswere also observed for A431 Human epithelial carcinoma cells, whichexhibited an over expressed level of EGFR. Erbitux/h-αPEG, but not thecontrol Erbitux antibodies, directed PEGylated compounds to beaccumulated on the surface of A431 cells (EGFR+) (FIG. 30B).

The anticancer effects of using BsAbs of example 4.1 to target Lipo-Doxto cancer cells was further examined in vitro. Results are depicted inFIGS. 31A and 31B.

It was confirmed that Herceptin/h-αPEG (FIG. 31A) and Erbitux/h-αPEG(FIG. 31B), but not control Abs, when respectively combined withLipo-Dox exhibited synergistic anti-cancer effects, indicating that thedouble-attack strategy help attain a higher level of tumor-killingeffect.

In a similar experiment, HER-2 positive SKBR-3 cells were pre-incubatedwith 5 μg/mL Herceptin/h-αPEG or Herceptin at 37° C. for 1 h. Afterwashing to remove unbound Abs, cells were then treated with gradedconcentrations of Lipo-Dox (9, 3, and 0.33 μg/mL) in triplicate for 6 h.Drug-containing medium was then replaced with fresh medium and allowedthe cells to continue incubation for an additional 72 hr. Cellular ATPsynthesis in the drug-treated cells was then compared with that of theuntreated cells.

It was found that cytotoxicity level was much higher in cellspre-treated with bi-specific Herceptin antibody and Lipo-Dox, than thatof the cells treated with either Herceptin alone or Lipo-Dox alone (FIG.32). The finding is in line with that of FIGS. 31A and 31B, in which asynergistic killing effect caused by Lipo-Dox and the anti-PEG BsAb wasobserved.

It will be understood that the above description of embodiments is givenby way of example only and that various modifications may be made bythose with ordinary skill in the art. The above specification, examplesand data provide a complete description of the structure and use ofexemplary embodiments of the invention. Although various embodiments ofthe invention have been described above with a certain degree ofparticularity, or with reference to one or more individual embodiments,those with ordinary skill in the art could make numerous alterations tothe disclosed embodiments without departing from the spirit or scope ofthis invention.

What is claimed is:
 1. A humanized bi-specific antibody against theterminal methoxy or hydroxyl group of polyethylene glycol (PEG) and atarget ligand on a cancer cell, comprising, a first antigen binding sitethat binds to the PEG, wherein the first antigen binding site comprisesa first VL-Cκ domain and a first VH-CH1 domain; and a second antigenbinding site that binds to the target ligand on the cancer cell,wherein, the first VL-Cκ domain comprises a CDR1 having the sequence ofSEQ ID NO: 221; a CDR2 having the sequence of SEQ ID NO: 222; and a CDR3having the sequence of SEQ ID NO: 223; and the first VH-CH1 domaincomprises a CDR1 having the sequence of SEQ ID NO: 224; a CDR2 havingthe sequence of SEQ ID NO: 225; and a CDR3 having the sequence of SEQ IDNO:
 226. 2. The humanized bi-specific antibody of claim 1, wherein thefirst VL-Cκ domain has the sequence of SEQ ID NO: 12, and the firstVH-CH1 domain has the sequence of SEQ ID NO:
 13. 3. The humanizedbi-specific antibody of claim 1, wherein the first antigen binding sitefurther comprises a Knob Hinge CH2-CH3 domain connecting to the firstVH-CH1 domain, wherein the Knob Hinge CH2-CH3 domain has the sequence ofSEQ ID NO:
 22. 4. The humanized bi-specific antibody of claim 1, whereinthe first antigen binding site and the second antigen binding site areFab or single chain variable fragment (scFv).
 5. The humanizedbi-specific antibody of claim 1, wherein the target ligand is EGFR,HER2, TAG-72, CD19 or CD20.
 6. A pharmaceutical kit comprising thehumanized bi-specific antibody of claim 1; and a PEGylated substance,wherein the substance is a protein, a peptide, or a nanoparticle,wherein the nanoparticle contains therein a chemotherapeutic drug or animaging agent.
 7. The pharmaceutical kit of claim 6, wherein thechemotherapeutic drug is adriamycin, amifostine, bleomycin, busulfan,cisplatin, carboplatin, oxaliplatin, camptothecin, CPT-11, cytosinearabinoside, chlorambucil, cyclophosphamide, cytarabine, daunorubicin,doxorubicin, docetaxel, dacarbazine, dactinomycin, etoposide,5-fluorouracil (5-FU), fluoxuridine, gemcitabine, hydroxyurea,ifosfamide, idarubicin, interferon beta, irinotecan, L-asparaginase,L-aspartic acid, lomustine, mechlorethamine, mitomycin, methotrexate,mitoxantrone, megestrol, melphalan, mercaptopurine, mitotane, paclitaxel(taxol), plicamycin, pentostatin, streptozocin, topotecan, tamoxifen,teniposide, thioguanine, vinblastine, vincristine, SN38 or a combinationthereof.
 8. The pharmaceutical kit of claim 6, wherein the imaging agentis a quantum dot (QD), a microbubble contrast agent, a fluorescence dye,a chelated radioisotope a paramagnetic iron or a gold nanoparticle. 9.The pharmaceutical kit of claim 6, wherein the protein is a chemokine ora cytokine; and the peptide is leuprolide, goserelin, octreotide,histrelin, abarelix, cetrorelix, degarelix, cilengtide, ATN-161, orIM862.
 10. A method for treating a subject suffering from a cancercomprising: mixing a first amount of the humanized bi-specific antibodyof claim 1 with a second amount of a PEGylated substance to form anassembly; and administering a therapeutically effective amount of theassembly either sequentially or concurrently to the subject to inhibitthe growth or metastasis of the cancer; wherein the PEGylated substanceis therapeutic and is a protein, a peptide, or a nanoparticle, whereinthe nanoparticle contains therein a chemotherapeutic drug.
 11. Themethod of claim 10, wherein the chemotherapeutic drug is adriamycin,amifostine, bleomycin, busulfan, cisplatin, carboplatin, oxaliplatin,camptothecin, CPT-11, cytosine arabinoside, chlorambucil,cyclophosphamide, cytarabine, daunorubicin, doxorubicin, docetaxel,dacarbazine, dactinomycin, etoposide, 5-fluorouracil (5-FU),fluoxuridine, gemcitabine, hydroxyurea, ifosfamide, idarubicin,interferon beta, irinotecan, L-asparaginase, L-aspartic acid, lomustine,mechlorethamine, mitomycin, methotrexate, mitoxantrone, megestrol,melphalan, mercaptopurine, mitotane, paclitaxel (taxol), plicamycin,pentostatin, streptozocin, topotecan, tamoxifen, teniposide,thioguanine, vinblastine, vincristine, SN38 or a combination thereof.12. The method of claim 10, wherein the protein is a chemokine or acytokine; and the peptide is leuprolide, goserelin, octreotide,histrelin, abarelix, cetrorelix, degarelix, cilengtide, ATN-161, orIM862.
 13. The method of claim 10, wherein the cancer is breast cancer,colorectal cancer, colon cancer, hepatic cancer, non-Hodgkin's lymphoma,lymphoma, pancreatic cancer, lung cancer, gastric cancer, prostatecancer, brain tumor, retinoblastoma, ovary cancer, cervical cancer,hematopoietic malignances, esophageal cancer, renal cell carcinoma,squamous cell carcinoma, glioma, or leukemia.
 14. A method of imagingtissues in a subject comprising: (a) mixing a first sufficient amount ofthe humanized bi-specific antibody of claim 1 and a second sufficientamount of a PEGylated imaging agent to form an assembly; (b) injectingthe assembly of the step (a) to the subject; and (c) imaging the tissuesof the subject by fluorescence imaging, electron spin resonance (ESR)imaging, X-ray imaging, computed tomography (CT), or magnetic resonanceimaging (MRI).